Delivered-To: tjphuhs@gmail.com Received: by 2002:a05:6000:298f:20b0:451:8158:aa77 with SMTP id gl15-n2csp512493wrb; Wed, 6 May 2026 11:59:58 -0700 (PDT) X-Received: by 2002:a05:620a:4404:b0:8ee:bae8:2bb8 with SMTP id af79cd13be357-904d5ffdea2mr667666485a.36.1778093998600; Wed, 06 May 2026 11:59:58 -0700 (PDT) ARC-Seal: i=1; a=rsa-sha256; t=1778093998; cv=none; d=google.com; s=arc-20240605; b=OEzU7+b2sH/jKMgSND0a9Xcg5C3EaxSxLCyqJ9F3seM1nwjdCtJ+1/nJhVBBm38st5 ntbLZKnnHlTbBTJghgeP2NzSBkqjTrM+W/XmkFLQhrtFuTMyyC9DZXiv8H9xeNYRpRQZ Kv/Z3vGU5h0/nWMN6jz0UQbz6UZi3aBRBD6JMZ5VTTVb9qKdkOifXTccHByQNga0TItu nAD1fgDlBgfzDlRkM3KOVZIGRIZWgthdRjUACefIItKFQYOvufBbSw1XZvxinCEwha/L g9dXy1/ye5yGDqIAyWOAh13efbPLfx4AlkEfkwT38unMYOc577N0iducCsCqYXdnNw8X bCoQ== ARC-Message-Signature: i=1; a=rsa-sha256; c=relaxed/relaxed; d=google.com; s=arc-20240605; h=list-unsubscribe-post:list-unsubscribe:list-post:list-id :list-archive:list-url:list-owner:reply-to:in-reply-to:references :sender:feedback-id:date:message-id:to:from:subject:mime-version :dkim-signature:dkim-signature; bh=tZ46i8/7Z5sHmrWYxVkvKjdV2HAMtQTVR+T1h5UWhnA=; fh=9zP21OW67FFZD2VV42mGudo540Qp4aalMWxJB5kMYug=; b=RrVyhhlIoQ9ypCINPK5XQSoBQfMh7ljWYwtu812D++NSrSaYmxu44E25rYpvMVCB4E sQwoN6a4PVRs4TicmS9F2s7PYBm4jCybplXP7cYUsugWBHBFljUyJo/LBW85XvvjAq3J bHb/yYQaQgvt/8Ro18Jov2HFHnyhhThHRzyoTX+6R+gfxsNiQE75to/AQDRdKWY/ivZ8 Kt2BUQc1ao3baw8sYy55joPW2TaZkr3I7vpjBkIPWSx2qcuJZ933qOtDDT7yemCZz6WP pS0UuV6I1auWY68AinlzsLoMRHiNX5BD1nOOzPAaNiHySIJkpDdT0rp1Rvd/JvHhTwi/ L/+A==; dara=google.com ARC-Authentication-Results: i=1; mx.google.com; dkim=pass header.i=@mg-d0.substack.com header.s=mailo header.b=rP+gWHaY; dkim=pass header.i=@mailgun.org header.s=mg header.b=L2BGKeJ8; spf=pass (google.com: domain of bounce+91e48a.63af5d-tjphuhs=gmail.com@mg-d0.substack.com designates 159.112.244.10 as permitted sender) smtp.mailfrom="bounce+91e48a.63af5d-tjphuhs=gmail.com@mg-d0.substack.com"; dmarc=pass (p=REJECT sp=REJECT dis=NONE) header.from=substack.com Return-Path: Received: from v510.v5375b7fa.use4.send.mailgun.net (v510.v5375b7fa.use4.send.mailgun.net. [159.112.244.10]) by mx.google.com with UTF8SMTPS id af79cd13be357-8fc28da3470si1785815985a.98.2026.05.06.11.59.58 for (version=TLS1_2 cipher=ECDHE-ECDSA-AES128-GCM-SHA256 bits=128/128); Wed, 06 May 2026 11:59:58 -0700 (PDT) Received-SPF: pass (google.com: domain of bounce+91e48a.63af5d-tjphuhs=gmail.com@mg-d0.substack.com designates 159.112.244.10 as permitted sender) client-ip=159.112.244.10; Authentication-Results: mx.google.com; dkim=pass header.i=@mg-d0.substack.com header.s=mailo header.b=rP+gWHaY; dkim=pass header.i=@mailgun.org header.s=mg header.b=L2BGKeJ8; spf=pass (google.com: domain of bounce+91e48a.63af5d-tjphuhs=gmail.com@mg-d0.substack.com designates 159.112.244.10 as permitted sender) smtp.mailfrom="bounce+91e48a.63af5d-tjphuhs=gmail.com@mg-d0.substack.com"; dmarc=pass (p=REJECT sp=REJECT dis=NONE) header.from=substack.com DKIM-Signature: a=rsa-sha256; v=1; c=relaxed/relaxed; d=mg-d0.substack.com; q=dns/txt; s=mailo; t=1778093998; x=1778101198; h=List-Unsubscribe-Post: List-Unsubscribe: List-Post: List-Id: List-Archive: List-Owner: Reply-To: In-Reply-To: References: Sender: Sender: Date: Message-Id: To: To: From: From: Subject: Subject: Content-Type: Mime-Version: X-Feedback-Id; bh=tZ46i8/7Z5sHmrWYxVkvKjdV2HAMtQTVR+T1h5UWhnA=; b=rP+gWHaYJGlc0HgHfH98iSuZJv4MGWbf2pLyB+LZ4zyS4S9On+bksjFpmLuznzmdiDnU2FOUBF3Fc9jQLs/Ag+T3IJFQpATdaylBQFcCPF8JbDMLq3m4GbIz1VD8fUSwZGf8WuemCCWFCJlyAJM7VZUMCu1ONQdYxDvapr867aU= DKIM-Signature: a=rsa-sha256; v=1; c=relaxed/relaxed; d=mailgun.org; q=dns/txt; s=mg; t=1778093998; x=1778101198; h=List-Unsubscribe-Post: List-Unsubscribe: List-Post: List-Id: List-Archive: List-Owner: Reply-To: In-Reply-To: References: Sender: Sender: Date: Message-Id: To: To: From: From: Subject: Subject: Content-Type: Mime-Version: X-Feedback-Id; bh=tZ46i8/7Z5sHmrWYxVkvKjdV2HAMtQTVR+T1h5UWhnA=; b=L2BGKeJ8m3ibbnK118GyWkdkG4jFNCB2BFsan0N7uq5nvIRqnGP9ecji5JAHfy566zxYnjXcJiOKiL50A9nCwRO+zNQjnsikdAtK+uDbCW2fEM4qJAnYvwpaYtRKJB+QXD+atNAy61IidNgX9yKtpNDd/tLQLrEn/ZSgOeXBBfA= X-Mailgun-Sid: WyJkZWU4NyIsInRqcGh1aHNAZ21haWwuY29tIiwiNjNhZjVkIl0= X-Feedback-Id: postmaster@mg-d0.substack.com:post:6148c7d8a45790427cda307f:mailgun Received: by 939d1fed7624cfcdba6629e24546f67b99dcbdca9e9c1d71c625290f24ac5037 with HTTP id 69fb8fad12b51e904e75574a; Wed, 06 May 2026 18:59:57 GMT X-Mailgun-Sending-Ip: 159.112.244.10 Mime-Version: 1.0 Content-Type: multipart/alternative; boundary="c3d5585fa2c80c1ed93e1e7208fe36fab5c3c38cab25194c1c1544e34d5d" Subject: SS-31: The Mitochondrial Peptide With Way More Uses Than People Realize From: Derek from Research Radar To: tjphuhs@gmail.com X-Mailgun-Tag: post X-Mailgun-Track-Clicks: false Message-Id: <20260506185921.3.16591aed78499185@mg-d0.substack.com> Date: Wed, 6 May 2026 18:59:21 +0000 Feedback-Id: post-196696515:cat-post:pub-3365367:substack Sender: Derek from Research Radar References: In-Reply-To: Reply-To: Derek from Research Radar List-Owner: List-Url: List-Archive: List-Id: List-Post: List-Unsubscribe: List-Unsubscribe-Post: List-Unsubscribe=One-Click X-Mailgun-Variables: {"category": "post", "email_generated_at": "1778093997745", "is_freemail": "true", "post_audience": "everyone", "post_id": "196696515", "post_type": "newsletter", "pub_community_enabled": "true", "publication_id": "3365367", "subdomain": "derekpruski", "user_id": "273622398"} --c3d5585fa2c80c1ed93e1e7208fe36fab5c3c38cab25194c1c1544e34d5d Content-Type: text/plain; charset="utf-8" Content-Transfer-Encoding: quoted-printable View this post on the web at https://derekpruski.substack.com/p/ss-31-the-m= itochondrial-peptide-with Research and educational purposes only. Nothing in this piece is medical ad= vice. If you=E2=80=99re considering anything personally, that=E2=80=99s a c= onversation for a qualified clinician. Most of the SS-31 conversation in the peptide world stops at one sentence: = =E2=80=9Cit repairs mitochondria.=E2=80=9D And that=E2=80=99s true =E2=80= =94 but it massively undersells what this peptide actually does and where i= t=E2=80=99s been studied. When you start digging through the literature, SS-31 has clinical trial dat= a in places you probably wouldn=E2=80=99t expect. Kidney disease. Macular d= egeneration. Heart failure. Barth syndrome. Glaucoma. Hearing loss. Diabeti= c complications. Some of the most interesting research isn=E2=80=99t about = energy or aging in a generic sense =E2=80=94 it=E2=80=99s about specific or= gan systems that people don=E2=80=99t usually associate with mitochondrial = peptides. This piece walks through what SS-31 is, hits the mitochondrial mechanism qu= ickly so we have a foundation, and then spends most of the time on the appl= ications nobody talks about. What SS-31 Actually Is (The Quick Version) SS-31 =E2=80=94 also called elamipretide, MTP-131, and Bendavia in differen= t research contexts =E2=80=94 is a synthetic tetrapeptide. Four amino acids= , no more. It was discovered by Dr. Hazel Szeto at Weill Cornell Medical Co= llege, hence the =E2=80=9CSS=E2=80=9D naming. What makes it unique: SS-31 doesn=E2=80=99t just float around the cell. It selectively concentrat= es inside the inner mitochondrial membrane at concentrations 1,000 to 5,000= times higher than the surrounding tissue. That kind of targeting precision is rare for any compound, let alone a pept= ide. Once it gets there, it binds to a phospholipid called cardiolipin =E2=80=94= the structural backbone of the inner mitochondrial membrane. Cardiolipin i= s what holds the cristae (the folded inner structure of the mitochondria) i= n place, and it=E2=80=99s required for the electron transport chain to asse= mble properly. When cardiolipin gets damaged or oxidized, mitochondria lite= rally fall apart from the inside. SS-31 protects cardiolipin from peroxidation and stabilizes the membrane st= ructure. Net result: mitochondria stop leaking, ATP production goes back up= , ROS drops, and cells stop dying from energy failure. That=E2=80=99s the headline mechanism. Now the stuff people don=E2=80=99t t= alk about enough. The Kidney Story This is one of the most underrated areas of SS-31 research, and it makes to= tal sense once you understand the kidney=E2=80=99s biology. Why kidneys are mitochondria-dependent. The kidney is one of the most metab= olically demanding organs in the body. Specifically, the proximal tubules = =E2=80=94 the part of the nephron responsible for reabsorbing nutrients, el= ectrolytes, and water back into the bloodstream =E2=80=94 are packed with m= itochondria. They have to be, because reabsorption is an active transport p= rocess that requires enormous amounts of ATP. When mitochondria fail in the= kidney, the kidney fails. What the research shows. SS-31 has been studied across nearly every categor= y of kidney disease in research models =E2=80=94 acute kidney injury, ische= mia-reperfusion injury (the damage that happens when blood flow returns to = a tissue after being cut off), diabetic nephropathy, polycystic kidney dise= ase, atherosclerotic renal artery stenosis, and aging-related kidney declin= e. The atherosclerotic renal artery stenosis trial. This one is worth pulling = out specifically. In a Phase 2a clinical trial, patients undergoing stent r= evascularization for atherosclerotic renal artery stenosis received SS-31 i= nfusions. The peptide was well tolerated with no serious adverse events. Mo= re importantly, the research showed measurable improvements in renal blood = flow and oxygenation in the affected kidneys. This is real human data in a = serious, late-stage kidney condition. The mechanism in kidneys. SS-31 reduces tubular cell apoptosis (cells dying= from energy failure), reduces fibrosis (scarring that progressively destro= ys kidney function), and preserves mitochondrial structure in the proximal = tubules. In aging research, it=E2=80=99s been shown to reverse some age-rel= ated decline in kidney function in animal models. For anyone interested in longevity from a =E2=80=9Cpreserve organ function= =E2=80=9D angle, the kidneys are usually one of the first places to start f= ailing in older populations. SS-31 might be one of the most direct mitochon= drial tools available for that exact problem. The Eye Story This is the one almost nobody knows about, and it might be the most clinica= lly advanced application of SS-31 in humans. Why eyes are mitochondrial. The retina =E2=80=94 specifically the photorece= ptors and the retinal pigment epithelium (RPE) =E2=80=94 has one of the hig= hest mitochondrial densities of any tissue in the body. Vision is metabolic= ally expensive. Every time a photon hits a photoreceptor, mitochondria have= to fire to convert that signal into something the brain can read. As mitoc= hondria age, the photoreceptors start dying, and you get age-related macula= r degeneration (AMD). The ReCLAIM trials SS-31 has been studied in a series of clinical trials for dry AMD with nonc= entral geographic atrophy =E2=80=94 the early-to-intermediate form of the l= eading cause of irreversible blindness in people over 50. These trials are = called ReCLAIM and ReCLAIM-2, and they=E2=80=99ve been running through Phas= e 1 and Phase 2. Patients received subcutaneous SS-31 at 40 mg daily for 24 to 48 weeks. The= trials demonstrated: Good safety and tolerability Positive effects on visual function, particularly under low-luminance condi= tions (one of the first things to go in early AMD) Preservation of ellipsoid zone integrity (a marker of photoreceptor health = on retinal imaging) Currently in Phase 3 As of 2025, Stealth BioTherapeutics has Phase 3 trials running =E2=80=94 Re= NEW and ReGAIN =E2=80=94 with 360 patients each, evaluating SS-31 specifica= lly for dry AMD. This is genuinely advanced clinical development for a pept= ide. Beyond AMD Preclinical research has also shown effects on glaucoma (where retinal gang= lion cells die from mitochondrial dysfunction in the optic nerve), diabetic= retinopathy, and dry eye disease. The eye is mitochondria-dense, and SS-31= keeps showing up wherever mitochondria are the bottleneck. If you have family history of macular degeneration or you=E2=80=99re alread= y noticing low-light vision changes, this is an area of the literature wort= h understanding deeply. The Heart Story (Beyond Generic =E2=80=9CCardioprotection=E2=80=9D) I=E2=80=99m including this because most people who hear =E2=80=9CSS-31 help= s the heart=E2=80=9D assume it=E2=80=99s just generic cardioprotection. The= actual research is more specific and more interesting. Barth syndrome This is a rare X-linked genetic disease where boys are born with a defect i= n the TAZ gene, which makes the enzyme responsible for properly maturing ca= rdiolipin. Without functional cardiolipin, their mitochondria =E2=80=94 esp= ecially in the heart =E2=80=94 can=E2=80=99t form proper cristae structure.= They develop severe cardiomyopathy and skeletal muscle weakness, often in = infancy. SS-31 was tested in Barth syndrome patients in the TAZPOWER trial and its o= pen-label extension. Long-term treatment (48 weeks) showed significant impr= ovements in: 6-minute walk test performance Cardiac stroke volume Barth Syndrome Symptom Assessment scores SS-31 received orphan drug designation for Barth syndrome and is now FDA-ap= proved as Forzinity =E2=80=94 making it one of the very few peptides to mak= e it through to actual approval. HFpEF (heart failure with preserved ejection fraction) This is the heart failure type that=E2=80=99s notoriously difficult to trea= t. SS-31 has been studied here too, with mixed results =E2=80=94 improvemen= ts in mitochondrial bioenergetics measured at the molecular level, but the = functional cardiac improvements haven=E2=80=99t always translated. The PROG= RESS-HF trial is ongoing. The honest take: SS-31 has the strongest cardiac evidence in genetic cardio= lipin deficiency (Barth) and demonstrable mitochondrial heart disease. The = general =E2=80=9CI want to protect my heart=E2=80=9D use case has weaker ev= idence than the specific =E2=80=9Cmy mitochondria are failing in my heart m= uscle=E2=80=9D use case. Important distinction. The Neuroprotection Angle The brain is mitochondria-heavy, and SS-31 crosses the blood-brain barrier = =E2=80=94 though brain concentrations are lower than what you see in kidney= , heart, and skeletal muscle. Alzheimer=E2=80=99s disease (preclinical). In AD mouse models, SS-31 has be= en shown to reduce amyloid-beta accumulation, protect synaptic function, re= duce neuroinflammation, and preserve cognitive performance. The mechanism i= s what you=E2=80=99d expect =E2=80=94 neurons in AD brains have failing mit= ochondria, and SS-31 stabilizes them before the cells die. Parkinson=E2=80=99s disease (preclinical). Dopaminergic neurons are extreme= ly mitochondria-dependent. SS-31 protected dopaminergic neurons in MPTP-ind= uced PD models in mice and reduced motor deficits. Stroke and TBI. After a stroke or traumatic brain injury, the brain accumul= ates oxidative stress that causes secondary damage. SS-31 has shown protect= ion against this secondary injury phase in animal models. Anesthesia-induced cognitive decline. There=E2=80=99s a specific area of re= search on post-operative cognitive dysfunction in older patients exposed to= anesthesia like isoflurane. SS-31 prevented the cognitive deficits in aged= mice and preserved hippocampal mitochondrial function. Niche, but interest= ing if you know anyone facing major surgery in older age. Important caveat: almost all CNS data is preclinical. There=E2=80=99s no co= mpleted Phase 2 or Phase 3 SS-31 trial in Alzheimer=E2=80=99s or Parkinson= =E2=80=99s specifically, and the brain concentrations achieved with subcuta= neous dosing are lower than other tissues. Use this section as a =E2=80=9Cp= romising direction=E2=80=9D rather than =E2=80=9Cestablished outcome.=E2=80= =9D The Less-Discussed Applications A quick rundown of areas where SS-31 has preclinical research that almost n= ever gets talked about: Hearing loss. SS-31 has been studied for noise-induced and age-related hear= ing loss. Hair cells in the cochlea are mitochondria-rich and die from oxid= ative damage. SS-31 protected them in animal models of noise exposure. Diabetic complications. Beyond diabetic nephropathy and retinopathy mention= ed above, SS-31 has been studied in diabetic cardiomyopathy and peripheral = nerve damage. The common thread: high glucose damages mitochondria across m= ultiple tissues, and SS-31 protects them. Osteoarthritis. Cartilage cells (chondrocytes) have failing mitochondria in= OA, and SS-31 has shown chondroprotective effects in animal models. Skin aging. Some early research on SS-31 and skin elasticity, photoaging pr= otection, and wound healing =E2=80=94 though most of this is in vitro or in= animal models, not human trials. Skeletal muscle aging (sarcopenia). In aged mice, SS-31 restored ATP produc= tion in skeletal muscle within roughly an hour of administration, improved = exercise tolerance, and increased muscle mass over longer treatment periods= =2E The MOTS-c-style use case overlaps=20= here, but SS-31 works on a different m= echanism (membrane stabilization vs. metabolic signaling). Sepsis and ischemia-reperfusion injury. In critical care research models, S= S-31 has shown protection against multi-organ failure driven by mitochondri= al collapse. The Honest Take on SS-31 A few things that don=E2=80=99t get said enough. It=E2=80=99s one of the only peptides with serious human clinical trial dat= a. Most peptides we talk about have preclinical research and anecdotal prot= ocols. SS-31 has Phase 2 and Phase 3 trials across multiple indications, FD= A approval in Barth syndrome (as Forzinity), and a pharmaceutical company (= Stealth BioTherapeutics) running a full development pipeline behind it. Not every trial has been a win. The MMPOWER-3 trial in primary mitochondria= l myopathy missed its primary endpoint of 6-minute walk test improvement, t= hough patients reported less fatigue. Some HFpEF and HFrEF trials have show= n molecular improvements without translating to functional cardiac changes.= The compound isn=E2=80=99t a cure-all, and the literature reflects that ho= nestly. It works best where mitochondria are the bottleneck. SS-31 is a precision t= ool, not a generic =E2=80=9Cfeel better=E2=80=9D peptide. In conditions whe= re mitochondrial dysfunction is genuinely the upstream driver =E2=80=94 Bar= th syndrome, certain kidney injuries, dry AMD, mitochondrial disease =E2=80= =94 the effects are real. In conditions where mitochondria are downstream o= f bigger problems, SS-31 can support but won=E2=80=99t reverse the underlyi= ng issue. It pairs with =E2=80=94 not replaces =E2=80=94 other mitochondrial tools. U= rolithin A drives mitophagy (clearing damaged mitochondria). MOTS-c drives = metabolic signaling and AMPK activation. SS-31 stabilizes the structural me= mbrane of existing mitochondria. These are three different mechanisms opera= ting on three different layers of the same system. They=E2=80=99re compleme= ntary, not competitive. What the Research Dosing Looks Like Across the major clinical trials, the standard research dose has been 40 mg= subcutaneously once daily. That=E2=80=99s the dose used in the Barth syndr= ome trials, the dry AMD ReCLAIM and ReCLAIM-2 trials, and the heart failure= trials. Treatment duration in the literature ranges from 4 weeks (cardiac trials) t= o 48 weeks or longer (Barth syndrome, AMD). Effects on mitochondrial functi= on in tissues like skeletal muscle have been observed within hours, but str= uctural and functional benefits in conditions like AMD, Barth, and kidney d= isease typically take months of continuous dosing. Half-life is short =E2=80=94 about 2 to 4 hours in plasma =E2=80=94 but tis= sue accumulation is what matters because of the cardiolipin binding affinit= y. Oral bioavailability is poor; subcutaneous is the standard research rout= e. Final Thoughts SS-31 is one of the few peptides where the breadth of the research actually= matches the hype around it. The mitochondrial repair story is real, but th= e more interesting story is the specific organ systems where it=E2=80=99s b= een studied at depth =E2=80=94 kidneys, eyes, hearts with genetic mitochond= rial disease. If aging is a story about energy failure cascading through one tissue at a = time, SS-31 is a tool that addresses the structural integrity of the energy= production system itself. Not the inputs (NAD+, CoQ10), not the cleanup (m= itophagy via UA), but the actual physical membrane where ATP gets made. That=E2=80=99s a different layer of the cellular machinery than most other = longevity tools. And that=E2=80=99s why it deserves to be understood for mo= re than just =E2=80=9Cit helps mitochondria.=E2=80=9D This is for research and educational purposes only. Nothing in this piece i= s medical advice, and this isn=E2=80=99t a recommendation to use SS-31 pers= onally. If you=E2=80=99re interested in the topic for any non-research reas= on, that=E2=80=99s a conversation for a qualified medical professional who = knows your situation. If this was useful, share it with someone who=E2=80=99s been chasing the lo= ngevity rabbit hole and only knows SS-31 as =E2=80=9Cthe mitochondria one= =E2=80=9D =E2=80=94 and let me know in the comments what underrated compoun= d you=E2=80=99d like me to break down next. =E2=80=94 Derek References Foundational mechanism Szeto HH. First-in-class cardiolipin-protective compound as a therapeutic a= gent to restore mitochondrial bioenergetics. Br J Pharmacol. 2014;171(8):20= 29-2050. Zhao W, Xu Z, Cao J, et al. Mitochondrial protein interaction landscape of = SS-31. Proc Natl Acad Sci USA. 2020;117(36):22247-22255. Kidney disease comprehensive review Wang Z, Chen Z, Li B, et al. SS-31, a Mitochondria-Targeting Peptide, Ameli= orates Kidney Disease. Oxidative Medicine and Cellular Longevity. 2022. Ful= l text [ https://substack.com/redirect/1fe740c9-560b-44d2-a2bb-0adb620fe3e4= ?j=3DeyJ1IjoiNGl3b2U2In0.sVDxRtmZ85v8kfdamY0krRXGMy3p768BWtuZifRB-Zs ] Atherosclerotic renal artery stenosis trial Saad A, et al. Phase 2a Clinical Trial of Mitochondrial Protection (Elamipr= etide) During Stent Revascularization in Patients With Atherosclerotic Rena= l Artery Stenosis. Circ Cardiovasc Interv. 2017;10(9):e005487. Dry AMD Phase 1 trial (ReCLAIM) Mettu PS, Allingham MJ, Cousins SW. Phase 1 Clinical Trial of Elamipretide = in Dry Age-Related Macular Degeneration and Noncentral Geographic Atrophy: = ReCLAIM NCGA Study. Ophthalmol Sci. 2022;2(1):100086. Full text [ https://s= ubstack.com/redirect/35da6e17-5c61-4644-8fcd-253165dbdf5f?j=3DeyJ1IjoiNGl3b= 2U2In0.sVDxRtmZ85v8kfdamY0krRXGMy3p768BWtuZifRB-Zs ] Dry AMD Phase 2 trial (ReCLAIM-2) ReCLAIM-2: A Randomized Phase II Clinical Trial Evaluating Elamipretide in = Age-related Macular Degeneration, Geographic Atrophy Growth, Visual Functio= n, and Ellipsoid Zone Preservation. Ophthalmology Science. 2024. Full text = [ https://substack.com/redirect/e00344cb-3f97-4bad-b525-a0e6ae973f1f?j=3Dey= J1IjoiNGl3b2U2In0.sVDxRtmZ85v8kfdamY0krRXGMy3p768BWtuZifRB-Zs ] Barth syndrome trial (TAZPOWER) Reid Thompson W, et al. A phase 2/3 randomized clinical trial followed by a= n open-label extension to evaluate the effectiveness of elamipretide in Bar= th syndrome. Genet Med. 2021;23(3):471-478. Comprehensive 2025 review Elamipretide: A Review of Its Structure, Mechanism of Action, and Therapeut= ic Potential. Int J Mol Sci. 2025;26(3):944. Full text [ https://substack.c= om/redirect/af9fa280-8b39-4b6c-b481-0b5be1767f23?j=3DeyJ1IjoiNGl3b2U2In0.sV= DxRtmZ85v8kfdamY0krRXGMy3p768BWtuZifRB-Zs ] Neuroprotection review Neuroprotective Effects of a Small Mitochondrially-Targeted Tetrapeptide El= amipretide in Neurodegeneration. Front Integr Neurosci. 2021;15:747901. Ful= l text [ https://substack.com/redirect/b5dbd811-3f64-4b52-9c6c-c088c0c3f253= ?j=3DeyJ1IjoiNGl3b2U2In0.sVDxRtmZ85v8kfdamY0krRXGMy3p768BWtuZifRB-Zs ] Aging skeletal muscle Campbell MD, Marcinek DJ, et al. Improving mitochondrial function with SS-3= 1 reverses age-related redox stress and improves exercise tolerance in aged= mice. Free Radic Biol Med. 2019. Alzheimer=E2=80=99s disease (preclinical) Reddy PH, Manczak M, Kandimalla R. Mitochondria-targeted small molecule SS3= 1: a potential candidate for the treatment of Alzheimer=E2=80=99s disease. = Hum Mol Genet. 2017;26(8):1483-1496. Independent assessment Alzheimer=E2=80=99s Drug Discovery Foundation Cognitive Vitality Report =E2= =80=94 SS-31 [ https://substack.com/redirect/6a12e434-a54a-4ab4-945b-963a3b= e38b6d?j=3DeyJ1IjoiNGl3b2U2In0.sVDxRtmZ85v8kfdamY0krRXGMy3p768BWtuZifRB-Zs = ] Unsubscribe https://substack.com/redirect/2/eyJlIjoiaHR0cHM6Ly9kZXJla3BydXN= raS5zdWJzdGFjay5jb20vYWN0aW9uL2Rpc2FibGVfZW1haWw_dG9rZW49ZXlKMWMyVnlYMmxrSW= pveU56TTJNakl6T1Rnc0luQnZjM1JmYVdRaU9qRTVOalk1TmpVeE5Td2lhV0YwSWpveE56YzRNR= Gt6T1RrM0xDSmxlSEFpT2pFNE1EazJNams1T1Rjc0ltbHpjeUk2SW5CMVlpMHpNelkxTXpZM0lp= d2ljM1ZpSWpvaVpHbHpZV0pzWlY5bGJXRnBiQ0o5LmVqdVlaRmNfOG5uTHVNRTNPWG9PR1Rtbm4= 3cEtQcGFTOFFCcVY4bzh5QUkiLCJwIjoxOTY2OTY1MTUsInMiOjMzNjUzNjcsImYiOnRydWUsIn= UiOjI3MzYyMjM5OCwiaWF0IjoxNzc4MDkzOTk3LCJleHAiOjIwOTM2Njk5OTcsImlzcyI6InB1Y= i0wIiwic3ViIjoibGluay1yZWRpcmVjdCJ9.kgZ8g1GRtt1A082v6ZOlhya_r3rGs3aCerucd5u= uJIE? --c3d5585fa2c80c1ed93e1e7208fe36fab5c3c38cab25194c1c1544e34d5d Content-Type: text/html; charset="utf-8" Content-Transfer-Encoding: quoted-printable = SS-31: The Mitochondrial Peptide With Way More Uses Than People Realize</ti= tle><style> @media (max-width: 1024px) { .typography .pullquote-align-left, .typography.editor .pullquote-align-left, .typography .pullquote-align-right, .typography.editor .pullquote-align-right, .typography .pullquote-align-wide, .typography.editor .pullquote-align-wide, .typography .pullquote-align-center, .typography.editor .pullquote-align-center { float: none; margin: 0 auto; width: 100%; max-width: 100%; } } @media all and (-ms-high-contrast: none), (-ms-high-contrast: active) { .typography .markup table.image-wrapper img, .typography.editor .markup table.image-wrapper img, .typography .markup table.kindle-wrapper img, .typography.editor .markup table.kindle-wrapper img { max-width: 550px; } } @media (min-width: 1024px) { .typography:not(:has(#toc)) .captioned-image-container figure:has(> a.ima= ge2-offset-left), .typography.editor:not(:has(#toc)) .captioned-image-container figure:has(= > a.image2-offset-left) { margin-left: var(--image-offset-margin); } .typography:not(:has(#toc)) .captioned-image-container figure:has(> a.ima= ge2-offset-right), .typography.editor:not(:has(#toc)) .captioned-image-container figure:has(= > a.image2-offset-right) { margin-right: var(--image-offset-margin); } } @media (min-width: 1300px) { .typography .captioned-image-container figure:has(> a.image2-offset-left)= , .typography.editor .captioned-image-container figure:has(> a.image2-offse= t-left) { margin-left: var(--image-offset-margin); } .typography .captioned-image-container figure:has(> a.image2-offset-right= ), .typography.editor .captioned-image-container figure:has(> a.image2-offse= t-right) { margin-right: var(--image-offset-margin); } } @media (max-width: 1024px) { .typography, .typography.editor { /* Disable offset on mobile/tablet */ } .typography .captioned-image-container figure:has(> a.image2-align-left), .typography.editor .captioned-image-container figure:has(> a.image2-align= -left), .typography .captioned-image-container figure:has(> a.image2-align-right)= , .typography.editor .captioned-image-container figure:has(> a.image2-align= -right) { float: none; margin: 1em auto; max-width: 100%; width: auto; padding: 0; } .typography .captioned-image-container figure:has(> a.image2-align-left.t= hefp), .typography.editor .captioned-image-container figure:has(> a.image2-align= -left.thefp), .typography .captioned-image-container figure:has(> a.image2-align-right.= thefp), .typography.editor .captioned-image-container figure:has(> a.image2-align= -right.thefp) { margin: 1em auto; } .typography .captioned-image-container figure:has(> a.image2-offset-left)= , .typography.editor .captioned-image-container figure:has(> a.image2-offse= t-left), .typography .captioned-image-container figure:has(> a.image2-offset-right= ), .typography.editor .captioned-image-container figure:has(> a.image2-offse= t-right) { margin: 1em auto; } .typography .captioned-image-container figure:has(> a.image2-align-left) = =2Eimage2-inset, .typography.editor .captioned-image-container figure:has(> a.image2-align= -left) .image2-inset, .typography .captioned-image-container figure:has(> a.image2-align-right)= .image2-inset, .typography.editor .captioned-image-container figure:has(> a.image2-align= -right) .image2-inset { display: block; justify-content: initial; } } @media (max-width: 768px) { .typography .markup div.sponsorship-campaign-embed, .typography.editor .markup div.sponsorship-campaign-embed { margin-top: 24px; margin-bottom: 24px; } .typography .markup div.sponsorship-campaign-embed:first-child, .typography.editor .markup div.sponsorship-campaign-embed:first-child { margin-top: 0px; } } @media screen and (max-width: 650px) { .typography .markup div.youtube-overlay, .typography.editor .markup div.youtube-overlay, .typography .markup div.vimeo-overlay, .typography.editor .markup div.vimeo-overlay { display: none !important; } } @media screen and (max-width: 370px) { .typography .markup div.tiktok-wrap, .typography.editor .markup div.tiktok-wrap { width: calc(95vw - 32px); height: calc((95vw - 32px - 2px) / 0.485714); } } @media screen and (max-width: 650px) { .typography .markup div.embedded-publication-wrap .embedded-publication.s= how-subscribe, .typography.editor .markup div.embedded-publication-wrap .embedded-public= ation.show-subscribe { padding: 24px; } } @media screen and (max-width: 650px) { .typography .markup div.subscription-widget-wrap .subscription-widget.sho= w-subscribe, .typography.editor .markup div.subscription-widget-wrap .subscription-wid= get.show-subscribe, .typography .markup div.subscription-widget-wrap-editor .subscription-wid= get.show-subscribe, .typography.editor .markup div.subscription-widget-wrap-editor .subscript= ion-widget.show-subscribe, .typography .markup div.captioned-button-wrap .subscription-widget.show-s= ubscribe, .typography.editor .markup div.captioned-button-wrap .subscription-widget= =2Eshow-subscribe { padding: 0px 24px; } } @media screen and (max-width: 650px) { .typography .markup div.subscription-widget-wrap .subscription-widget.sho= w-subscribe .subscription-widget-subscribe .button, .typography.editor .markup div.subscription-widget-wrap .subscription-wid= get.show-subscribe .subscription-widget-subscribe .button, .typography .markup div.subscription-widget-wrap-editor .subscription-wid= get.show-subscribe .subscription-widget-subscribe .button, .typography.editor .markup div.subscription-widget-wrap-editor .subscript= ion-widget.show-subscribe .subscription-widget-subscribe .button, .typography .markup div.captioned-button-wrap .subscription-widget.show-s= ubscribe .subscription-widget-subscribe .button, .typography.editor .markup div.captioned-button-wrap .subscription-widget= =2Eshow-subscribe .subscription-widget-subscribe .button { padding: 10px 12px; min-width: 110px; } } @media (max-width: 650px) { .typography .markup .twitter-embed, .typography.editor .markup .twitter-embed, .typography .markup .tweet, .typography.editor .markup .tweet { padding: 12px; } } @media (max-width: 650px) { .typography .markup .twitter-embed .tweet-text, .typography.editor .markup .twitter-embed .tweet-text, .typography .markup .tweet .tweet-text, .typography.editor .markup .tweet .tweet-text { font-size: 14px; line-height: 20px; } } @media (max-width: 650px) { .typography .markup .twitter-embed .tweet-photos-container.two, .typography.editor .markup .twitter-embed .tweet-photos-container.two, .typography .markup .tweet .tweet-photos-container.two, .typography.editor .markup .tweet .tweet-photos-container.two, .typography .markup .twitter-embed .tweet-photos-container.three, .typography.editor .markup .twitter-embed .tweet-photos-container.three, .typography .markup .tweet .tweet-photos-container.three, .typography.editor .markup .tweet .tweet-photos-container.three, .typography .markup .twitter-embed .tweet-photos-container.four, .typography.editor .markup .twitter-embed .tweet-photos-container.four, .typography .markup .tweet .tweet-photos-container.four, .typography.editor .markup .tweet .tweet-photos-container.four { height: 200px; } } @media (max-width: 650px) { .typography .markup .twitter-embed a.expanded-link .expanded-link-img, .typography.editor .markup .twitter-embed a.expanded-link .expanded-link-= img, .typography .markup .tweet a.expanded-link .expanded-link-img, .typography.editor .markup .tweet a.expanded-link .expanded-link-img { max-height: 180px; } } @media (max-width: 650px) { .typography .markup .twitter-embed a.expanded-link .expanded-link-descrip= tion, .typography.editor .markup .twitter-embed a.expanded-link .expanded-link-= description, .typography .markup .tweet a.expanded-link .expanded-link-description, .typography.editor .markup .tweet a.expanded-link .expanded-link-descript= ion { display: none; } } @media screen and (max-width: 650px) { .typography .markup .apple-podcast-container, .typography.editor .markup .apple-podcast-container { width: unset; } } @media (max-width: 420px) { .typography .markup .install-substack-app-embed img.install-substack-app-= embed-img, .typography.editor .markup .install-substack-app-embed img.install-substa= ck-app-embed-img { margin: 0 auto 16px auto; } } @media (max-width: 420px) { .typography .markup .install-substack-app-embed .install-substack-app-emb= ed-text, .typography.editor .markup .install-substack-app-embed .install-substack-= app-embed-text { margin: 0 0 12px 0; max-width: 100%; width: auto; text-align: center; } } @media (max-width: 420px) { .typography .markup .install-substack-app-embed .install-substack-app-emb= ed-link, .typography.editor .markup .install-substack-app-embed .install-substack-= app-embed-link { display: flex; justify-content: center; } } @media screen and (min-width: 481px) { .share-button-container { height: 38px; } } @media screen and (min-width: 481px) { .share-button-container a.comment { height: 38px; line-height: 38px; padding-right: 10px; } } @media screen and (max-width: 480px) { .share-button-container .separator { display: block; margin: 0; height: 8px; border-left: none; } } @media screen and (max-width: 480px) { .share-button-container a.share.first img { padding-left: 0; } } @media screen and (min-width: 481px) { .share-button-container a.mobile { display: none !important; } } @media screen and (min-width: 541px) { .settings-add-pub-modal-wrapper .container .add-recommending-pub-modal-co= ntainer { padding: 36px; height: 680px; } } @media screen and (min-width: 541px) { .settings-add-pub-modal-wrapper .container .add-recommending-pub-modal-co= ntainer .footer { position: absolute; bottom: 36px; margin: 0px; } } @media screen and (max-width: 650px) { .header-anchor-parent { display: none; } } @media screen and (max-width: 768px) { .post { padding: 16px 0 0 0; } } @media screen and (max-width: 650px) { .post .post-header .post-label { margin-top: 8px; } } @media screen and (max-width: 650px) { .post .post-header .meta-author-wrap.alternative-meta .meta-right-column = =2Epost-meta { margin-top: 6px; } } @media screen and (max-width: 650px) { .post .footer-facepile-container { height: 64px; padding: 0 16px; display: flex; align-items: center; justify-content: flex-start; width: 100%; } } @media screen and (max-width: 650px) { .post .post-footer.use-separators { justify-content: center; } } @media screen and (max-width: 650px) { .post .post-footer.next-prev { height: 64px; justify-content: space-between; box-sizing: border-box; } } @media screen and (max-width: 650px) { .post-contributor-footer .post-contributor-bio-table { display: block; } .post-contributor-footer .post-contributor-bio-table-row { display: flex; flex-direction: row; } .post-contributor-footer .post-contributor-bio-userhead-cell, .post-contributor-footer .post-contributor-bio-body-cell { display: block; } .post-contributor-footer .post-contributor-bio-body-cell { flex-grow: 1; } .post-contributor-footer .post-contributor-bio-body-table { display: block; } .post-contributor-footer .post-contributor-bio-body-table-row { display: block; } .post-contributor-footer .post-contributor-bio-copy-cell, .post-contributor-footer .post-contributor-bio-controls-cell { display: block; } .post-contributor-footer .post-contributor-bio-copy-cell { margin: 0 0 16px 0; } .post-contributor-footer .post-contributor-bio-controls-cell { width: auto; } .post-contributor-footer .post-contributor-bio-controls { margin: auto; } .post-contributor-footer .post-contributor-bio-controls .button.primary { width: 100%; } .post-contributor-footer .post-contributor-bio-text { font-size: 14px; } } @media screen and (min-width: 768px) { .post-silhouette { padding: 32px 0; } } @media screen and (max-width: 650px) { .post-silhouette .post-silhouette-title { margin-top: 10.44225025px; height: 120px; } } @media screen and (max-width: 650px) { .post-silhouette .post-silhouette-meta { width: 75%; } } @media screen and (max-width: 650px) { .post-silhouette .post-silhouette-meta.with-byline-image { margin: 20px 0; } } @media screen and (max-width: 650px) { .use-theme-bg .post-meta.alternative-meta .post-meta-item, .post-meta.alternative-meta .post-meta-item { padding-right: 16px; } } @media screen and (max-width: 370px) { .use-theme-bg .post-meta.alternative-meta .post-meta-item, .post-meta.alternative-meta .post-meta-item { font-size: 14px; } } @media screen and (max-width: 650px) { .use-theme-bg .post-meta.alternative-meta .post-meta-item.guest-author-pu= blication, .post-meta.alternative-meta .post-meta-item.guest-author-publication { display: none; } } @media screen and (max-width: 370px) { .post-meta .post-meta-item .post-meta-button { height: 36px !important; /* important to override in-line height style on emails */ } .post-meta .post-meta-item .post-meta-button .meta-button-label { display: none; } .post-meta .post-meta-item .post-meta-button > svg { margin-right: 0; } } @media screen and (max-width: 370px) { .post-meta .post-meta-item { font-size: 12px; } } @media screen and (max-width: 650px) { .post .floating-subscribe-button { bottom: 20px; right: 20px; } } @media (max-width: 1024px) { body .pullquote-align-left, body .pullquote-align-right, body .pullquote-align-wide, body .pullquote-align-center { float: none; margin: 0 auto; width: 100%; max-width: 100%; } } @media all and (-ms-high-contrast: none), (-ms-high-contrast: active) { body .markup table.image-wrapper img, body .markup table.kindle-wrapper img { max-width: 550px; } } @media (min-width: 1024px) { body:not(:has(#toc)) .captioned-image-container figure:has(> a.image2-off= set-left) { margin-left: var(--image-offset-margin); } body:not(:has(#toc)) .captioned-image-container figure:has(> a.image2-off= set-right) { margin-right: var(--image-offset-margin); } } @media (min-width: 1300px) { body .captioned-image-container figure:has(> a.image2-offset-left) { margin-left: var(--image-offset-margin); } body .captioned-image-container figure:has(> a.image2-offset-right) { margin-right: var(--image-offset-margin); } } @media (max-width: 1024px) { body { /* Disable offset on mobile/tablet */ } body .captioned-image-container figure:has(> a.image2-align-left), body .captioned-image-container figure:has(> a.image2-align-right) { float: none; margin: 1em auto; max-width: 100%; width: auto; padding: 0; } body .captioned-image-container figure:has(> a.image2-align-left.thefp), body .captioned-image-container figure:has(> a.image2-align-right.thefp) = { margin: 1em auto; } body .captioned-image-container figure:has(> a.image2-offset-left), body .captioned-image-container figure:has(> a.image2-offset-right) { margin: 1em auto; } body .captioned-image-container figure:has(> a.image2-align-left) .image2= -inset, body .captioned-image-container figure:has(> a.image2-align-right) .image= 2-inset { display: block; justify-content: initial; } } @media (max-width: 768px) { body .markup div.sponsorship-campaign-embed { margin-top: 24px; margin-bottom: 24px; } body .markup div.sponsorship-campaign-embed:first-child { margin-top: 0px; } } @media screen and (max-width: 650px) { body .markup div.youtube-overlay, body .markup div.vimeo-overlay { display: none !important; } } @media screen and (max-width: 370px) { body .markup div.tiktok-wrap { width: calc(95vw - 32px); height: calc((95vw - 32px - 2px) / 0.485714); } } @media screen and (max-width: 650px) { body .markup div.embedded-publication-wrap .embedded-publication.show-sub= scribe { padding: 24px; } } @media screen and (max-width: 650px) { body .markup div.subscription-widget-wrap .subscription-widget.show-subsc= ribe, body .markup div.subscription-widget-wrap-editor .subscription-widget.sho= w-subscribe, body .markup div.captioned-button-wrap .subscription-widget.show-subscrib= e { padding: 0px 24px; } } @media screen and (max-width: 650px) { body .markup div.subscription-widget-wrap .subscription-widget.show-subsc= ribe .subscription-widget-subscribe .button, body .markup div.subscription-widget-wrap-editor .subscription-widget.sho= w-subscribe .subscription-widget-subscribe .button, body .markup div.captioned-button-wrap .subscription-widget.show-subscrib= e .subscription-widget-subscribe .button { padding: 10px 12px; min-width: 110px; } } @media (max-width: 650px) { body .markup .twitter-embed, body .markup .tweet { padding: 12px; } } @media (max-width: 650px) { body .markup .twitter-embed .tweet-text, body .markup .tweet .tweet-text { font-size: 14px; line-height: 20px; } } @media (max-width: 650px) { body .markup .twitter-embed .tweet-photos-container.two, body .markup .tweet .tweet-photos-container.two, body .markup .twitter-embed .tweet-photos-container.three, body .markup .tweet .tweet-photos-container.three, body .markup .twitter-embed .tweet-photos-container.four, body .markup .tweet .tweet-photos-container.four { height: 200px; } } @media (max-width: 650px) { body .markup .twitter-embed a.expanded-link .expanded-link-img, body .markup .tweet a.expanded-link .expanded-link-img { max-height: 180px; } } @media (max-width: 650px) { body .markup .twitter-embed a.expanded-link .expanded-link-description, body .markup .tweet a.expanded-link .expanded-link-description { display: none; } } @media screen and (max-width: 650px) { body .markup .apple-podcast-container { width: unset; } } @media (max-width: 420px) { body .markup .install-substack-app-embed img.install-substack-app-embed-i= mg { margin: 0 auto 16px auto; } } @media (max-width: 420px) { body .markup .install-substack-app-embed .install-substack-app-embed-text= { margin: 0 0 12px 0; max-width: 100%; width: auto; text-align: center; } } @media (max-width: 420px) { body .markup .install-substack-app-embed .install-substack-app-embed-link= { display: flex; justify-content: center; } } @media screen and (min-width: 500px) { body .header a.logo { width: 42px; height: 42px; border-radius: 12px; } } @media screen and (max-width: 420px) { body .subscription-receipt table:first-of-type .subscription-amount .subs= cription-discount { width: 72px !important; } } @media screen and (min-width: 481px) { body .share-button-container { height: auto; } } @media screen and (max-width: 480px) { body .share-button-container .separator { display: block !important; margin: 0 !important; height: 8px !important; border-left: none !important; } } @media screen and (max-width: 650px) { .digest .item .post-meta-item.audience { display: none; } } @media screen and (min-width: 500px) { .digest-publication .logo img { width: 42px; height: 42px; border-radius: 8px; } } @media screen and (max-width: 650px) { .comments-page .container .comment-list .collapsed-reply { margin-left: calc(10 + 32px - 24px); } } @media screen and (max-width: 650px) { .comment > .comment-list { padding-left: 24px; } } @media screen and (max-width: 650px) { .finish-magic-login-modal .modal-content .container { padding: 24px 0; } } @media (max-width: 650px) { .reader2-text-b3 { line-height: 24px; } } @media screen and (max-width: 650px) { .reader2-text-h4 { line-height: 24px; } } @media screen and (min-width: 541px) { .user-profile-modal { padding-left: 12px; padding-right: 12px; } } @media screen and (max-width: 650px) { .subscribe-widget form.form .sideBySideWrap button.rightButton { padding: 10px 12px; } } @media screen and (min-width: 541px) { .pub-icon:hover .logo-hover, .feed-item-icon:hover .logo-hover { display: block; } } @media screen and (max-width: 650px) { .post-ufi.single-full-width-button .post-ufi-button-wrapper { width: 100%; padding: 16px; } .post-ufi.single-full-width-button .post-ufi-button-wrapper:empty { display: none; } .post-ufi.single-full-width-button .post-ufi-button { width: 100%; justify-content: center; } } @media screen and (max-width: 768px) { .file-embed-wrapper { padding: 0; } } @media screen and (max-width: 768px) { .file-embed-wrapper-editor { padding: 0; } } @media screen and (max-width: 768px) { .file-embed-wrapper-editor:active { padding: 0; } } @media only screen and (max-width: 650px) { .file-embed-button.wide, .file-embed-error-button.wide { display: none; } } @media only screen and (min-width: 630px) { .file-embed-button.narrow, .file-embed-error-button.narrow { display: none; } } @media screen and (min-width: 541px) { .audio-player-wrapper .audio-player { min-width: 500px; } } @media screen and (max-width: 650px) { .audio-player-wrapper .audio-player .audio-player-progress { border-left-width: 16px; border-right-width: 16px; } } @media screen and (max-width: 650px) { .audio-player-wrapper .audio-player .audio-player-progress .audio-player-= progress-bar .audio-player-progress-bar-popup { top: -54px; } } @media screen and (max-width: 650px) { .audio-player-wrapper-fancy .audio-player .audio-player-progress { border-left-width: 16px; border-right-width: 16px; } } @media screen and (max-width: 650px) { .audio-player-wrapper-fancy .audio-player .audio-player-progress .audio-p= layer-progress-bar .audio-player-progress-bar-popup { top: -54px; } } @media (min-width: 250px) { .audio-player-wrapper-fancy .audio-player { padding: 32px; } .audio-player-wrapper-fancy .audio-player .btn-group { display: flex; } .audio-player-wrapper-fancy .audio-player .btn-group .button:last-of-type= { display: block; } } @media (min-width: 300px) { .audio-player-wrapper-fancy .audio-player .btn-group { display: block; } .audio-player-wrapper-fancy .audio-player .btn-group .button:first-of-typ= e { display: block; } } @media (min-width: 350px) { .audio-player-wrapper-fancy .audio-player .audio-player-substack-logo { display: block; } .audio-player-wrapper-fancy .audio-player .audio-player-title { margin-top: 16px; } .audio-player-wrapper-fancy .audio-player .audio-player-hero-image-contai= ner { padding-top: 15%; width: 15%; display: block; } .audio-player-wrapper-fancy .audio-player .btn-group .button:first-of-typ= e { display: block; } .audio-player-wrapper-fancy .audio-player .audio-player-substack-logo { display: block; } } @media (min-width: 350px) { .audio-player-wrapper-fancy .audio-player .audio-player-hero-image-contai= ner { padding-top: 25%; width: 25%; display: block; } .audio-player-wrapper-fancy .audio-player .btn-group { display: flex; } .audio-player-wrapper-fancy .audio-player .btn-group .button:first-of-typ= e { display: block; } } @media (min-width: 400px) { .audio-player-wrapper-fancy .audio-player .audio-player-hero-image-contai= ner { padding-top: 40%; width: 40%; } } @media (max-width: 400px) { .audio-player-wrapper-fancy .audio-player .btn-group { margin-top: 12px; } .audio-player-wrapper-fancy .audio-player .btn-group .button { font-size: 13px; padding: 6px 12px; height: auto; margin-top: 10px; } } @media (min-width: 600px) { .audio-player-wrapper-fancy .audio-player .audio-player-hero-image-contai= ner { padding-top: 55%; width: 55%; } } @media (max-width: 650px) { .poll-editor-modal { min-width: calc(100% - 20px); } } @media (max-width: 750px) { .poll-embed .poll-anchor-target .poll-anchor-copy-button { left: 8px; top: 45px; } } @media not all and (min-resolution: 0.001dpcm) { @supports (-webkit-appearance: none) { p a:not(.primary.button), .post p:not(.button-wrapper) a:not(.primary.button), .footnote a.footnote-anchor:not(.primary.button), .thread-head .markup p:not(.button-wrapper) a:not(.primary.button) { color: #ff6719; text-decoration: none; } p a:not(.primary.button):hover, .post p:not(.button-wrapper) a:not(.primary.button):hover, .footnote a.footnote-anchor:not(.primary.button):hover, .thread-head .markup p:not(.button-wrapper) a:not(.primary.button):hove= r { text-decoration: underline; } } }</style></head><body class=3D"email-body" style=3D"font-kerning: auto;--im= age-offset-margin: -120px;"><img src=3D"https://eotrx.substackcdn.com/o/1eb= 1690adbc0e61d/p.gif?token=3DeyJtIjoiPDIwMjYwNTA2MTg1OTIxLjMuMTY1OTFhZWQ3ODQ= 5OTE4NUBtZy1kMC5zdWJzdGFjay5jb20-IiwidSI6MjczNjIyMzk4LCJyIjoidGpwaHVoc0BnbW= FpbC5jb20iLCJkIjoibWctZDAuc3Vic3RhY2suY29tIiwicCI6MTk2Njk2NTE1LCJ0IjoibmV3c= 2xldHRlciIsImEiOiJldmVyeW9uZSIsInMiOjMzNjUzNjcsImMiOiJwb3N0IiwiZiI6dHJ1ZSwi= cG9zaXRpb24iOiJ0b3AiLCJpYXQiOjE3NzgwOTM5OTcsImV4cCI6MTc4MDY4NTk5NywiaXNzIjo= icHViLTAiLCJzdWIiOiJlbyJ9.eAxHZjSqvSiX7mfY4S8z7IOdyK4KR8wwMCxE6ohoG9c" alt= =3D"" width=3D"1" height=3D"1" border=3D"0" style=3D"height:1px !important;= width:1px !important;border-width:0 !important;margin-top:0 !important;marg= in-bottom:0 !important;margin-right:0 !important;margin-left:0 !important;p= adding-top:0 !important;padding-bottom:0 !important;padding-right:0 !import= ant;padding-left:0 !important;"/><div class=3D"preview" style=3D"display:no= ne;font-size:1px;color:#333333;line-height:1px;max-height:0px;max-width:0px= ;opacity:0;overflow:hidden;">Most write-ups stop at “it repairs mitoc= hondria.” The actual research goes into kidneys, eyes, hearts with ge= netic disease, and a dozen other places nobody talks about.</div><div class= =3D"preview" style=3D"display:none;font-size:1px;color:#333333;line-height:= 1px;max-height:0px;max-width:0px;opacity:0;overflow:hidden;">͏   =   ­͏     ­͏     ­͏= ;     ­͏     ­͏     &#= 173;͏     ­͏     ­͏   &= #8199; ­͏     ­͏     ­͏=     ­͏     ­͏     = 73;͏     ­͏     ­͏   &#= 8199; ­͏     ­͏     ­͏ =     ­͏     ­͏     = 3;͏     ­͏     ­͏   = 199; ­͏     ­͏     ­͏ &= nbsp;   ­͏     ­͏     ­= ;͏     ­͏     ­͏   Q= 99; ­͏     ­͏     ­͏ &n= bsp;   ­͏     ­͏     ­= ͏     ­͏     ­͏   ̳= 9; ­͏     ­͏     ­͏ &nb= sp;   ­͏     ­͏     ­&= #847;     ­͏     ­͏    = ; ­͏     ­͏     ­͏ &nbs= p;   ­͏     ­͏     ­&#= 847;     ­͏     ­͏    = ­͏     ­͏     ­͏  = ;   ­͏     ­͏     ­= 47;     ­͏     ­͏     = ­͏     ­͏     ­͏  =   ­͏     ­͏     ­T= 7;     ­͏     ­͏     &= #173;͏     ­͏     ­͏   =   ­͏     ­͏     ­͏= ;     ­͏     ­͏     &#= 173;͏     ­͏     ­͏   &= #8199; ­͏     ­͏     ­͏=     ­͏     ­͏     = 73;͏     ­͏     ­͏   &#= 8199; ­͏     ­͏     ­͏ =     ­͏     ­͏     = 3;͏     ­͏     ­͏   = 199; ­͏     ­͏     ­͏ &= nbsp;   ­͏     ­͏     ­= ;͏     ­͏     ­͏   Q= 99; ­͏     ­͏     ­͏ &n= bsp;   ­͏     ­͏     ­= ͏     ­͏     ­͏   ̳= 9; ­͏     ­͏     ­͏ &nb= sp;   ­͏     ­͏     ­&= #847;     ­͏     ­͏    = ; ­͏     ­͏     ­͏ &nbs= p;   ­͏     ­͏     ­&#= 847;     ­͏     ­͏    = ­͏     ­͏     ­͏  = ;   ­͏     ­͏     ­= 47;     ­͏     ­͏     = ­͏     ­͏     ­͏  =   ­͏     ­͏     ­T= 7;     ­͏     ­͏     &= #173;͏     ­͏     ­͏   =   ­͏     ­͏     ­͏= ;     ­͏     ­͏     &#= 173;͏     ­͏     ­͏   &= #8199; ­͏     ­͏     ­͏=     ­͏     ­͏     = 73;͏     ­͏     ­͏   &#= 8199; ­͏     ­͏     ­͏ =     ­͏     ­͏     = 3;͏     ­͏     ­͏   = 199; ­͏     ­͏     ­͏ &= nbsp;   ­͏     ­͏     ­= ;͏     ­͏     ­͏   Q= 99; ­͏     ­͏     ­͏ &n= bsp;   ­͏     ­͏     ­= ͏     ­͏     ­͏   ̳= 9; ­͏     ­͏     ­͏ &nb= sp;   ­͏     ­͏     ­&= #847;     ­͏     ­͏    = ; ­͏     ­</div><table class=3D"email-body-contai= ner" role=3D"presentation" width=3D"100%" border=3D"0" cellspacing=3D"0" ce= llpadding=3D"0"><tbody><tr><td></td><td class=3D"content" width=3D"550"></t= d><td></td></tr><tr><td></td><td class=3D"content" width=3D"550" align=3D"l= eft"><div style=3D"font-size: 16px;line-height: 26px;max-width: 550px;width= : 100%;margin: 0 auto;overflow-wrap: break-word;"><table role=3D"presentati= on" width=3D"100%" border=3D"0" cellspacing=3D"0" cellpadding=3D"0"><tbody>= <tr><td align=3D"right" style=3D"height:20px;"><table role=3D"presentation"= width=3D"auto" border=3D"0" cellspacing=3D"0" cellpadding=3D"0"><tbody><tr= ><td style=3D"vertical-align:middle;"><span class=3D"pencraft pc-reset rese= t-IxiVJZ tw-font-body tw-text-ssm tw-text-substack-secondary" style=3D"font= -family: SF Pro Text, -apple-system, system-ui, BlinkMacSystemFont, Inter, = Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI= Emoji, Segoe UI Symbol;font-size: 13px;color: unset;list-style: none;text-= decoration: unset;margin: 0;"><div class=3D"pencraft pc-reset align-right-V= JbKw5 size-12-mmZ61m reset-IxiVJZ" style=3D"list-style: none;color: unset;t= ext-align: right;font-size: 12px;line-height: 16px;text-decoration: unset;m= argin: 0;"><span class=3D"pencraft pc-reset reset-IxiVJZ" translated=3D"" s= tyle=3D"list-style: none;color: unset;text-decoration: unset;margin: 0;">Fo= rwarded this email? <a class=3D"pencraft pc-reset decoration-underline-ClTk= Yc reset-IxiVJZ" href=3D"https://substack.com/redirect/2/eyJlIjoiaHR0cHM6Ly= 9kZXJla3BydXNraS5zdWJzdGFjay5jb20vc3Vic2NyaWJlP3V0bV9zb3VyY2U9ZW1haWwmdXRtX= 2NhbXBhaWduPWVtYWlsLXN1YnNjcmliZSZyPTRpd29lNiZuZXh0PWh0dHBzJTNBJTJGJTJGZGVy= ZWtwcnVza2kuc3Vic3RhY2suY29tJTJGcCUyRnNzLTMxLXRoZS1taXRvY2hvbmRyaWFsLXBlcHR= pZGUtd2l0aCIsInAiOjE5NjY5NjUxNSwicyI6MzM2NTM2NywiZiI6dHJ1ZSwidSI6MjczNjIyMz= k4LCJpYXQiOjE3NzgwOTM5OTcsImV4cCI6MjA5MzY2OTk5NywiaXNzIjoicHViLTAiLCJzdWIiO= iJsaW5rLXJlZGlyZWN0In0.e-8bmTmN0vWU0Kh4cOQ8GrppyIqY7k_wF546MPkq2HY?" style= =3D"list-style: none;color: unset;text-decoration: unset;margin: 0;-webkit-= text-decoration-line: underline;text-decoration-line: underline;">Subscribe= here</a> for more</span></div></span></td></tr></tbody></table></td></tr><= /tbody></table><div class=3D"post typography" dir=3D"auto" style=3D"--image= -offset-margin: -120px;padding: 32px 0 0 0;font-size: 16px;line-height: 26p= x;"><div class=3D"post-header" role=3D"region" aria-label=3D"Post header" s= tyle=3D"font-size: 16px;line-height: 26px;"><h1 class=3D"post-title publish= ed title-X77sOw" dir=3D"auto" style=3D"direction: auto;text-align: start;un= icode-bidi: isolate;color: rgb(54,55,55);font-family: 'SF Pro Display',-app= le-system-headline,system-ui,-apple-system,BlinkMacSystemFont,'Segoe UI',Ro= boto,Helvetica,Arial,sans-serif,'Apple Color Emoji','Segoe UI Emoji','Segoe= UI Symbol';font-weight: bold;-webkit-font-smoothing: antialiased;-moz-osx-= font-smoothing: antialiased;-webkit-appearance: optimizelegibility;-moz-app= earance: optimizelegibility;appearance: optimizelegibility;margin: 0;line-h= eight: 36px;font-size: 32px;"><a href=3D"https://substack.com/app-link/post= ?publication_id=3D3365367&post_id=3D196696515&utm_source=3Dpost-email-title= &utm_campaign=3Demail-post-title&isFreemail=3Dtrue&r=3D4iwoe6&token=3DeyJ1c= 2VyX2lkIjoyNzM2MjIzOTgsInBvc3RfaWQiOjE5NjY5NjUxNSwiaWF0IjoxNzc4MDkzOTk3LCJl= eHAiOjE3ODA2ODU5OTcsImlzcyI6InB1Yi0zMzY1MzY3Iiwic3ViIjoicG9zdC1yZWFjdGlvbiJ= 9.HRxTiWKoPv9sBLWcItbb-1Itf6pyvKSmY4q_P5Xrwl0" style=3D"color: rgb(54,55,55= );text-decoration: none;">SS-31: The Mitochondrial Peptide With Way More Us= es Than People Realize</a></h1><h3 class=3D"subtitle subtitle-HEEcLo" dir= =3D"auto" style=3D"direction: auto;text-align: start;unicode-bidi: isolate;= font-family: 'SF Pro Display',-apple-system-headline,system-ui,-apple-syste= m,BlinkMacSystemFont,'Segoe UI',Roboto,Helvetica,Arial,sans-serif,'Apple Co= lor Emoji','Segoe UI Emoji','Segoe UI Symbol';font-weight: normal;-webkit-f= ont-smoothing: antialiased;-moz-osx-font-smoothing: antialiased;-webkit-app= earance: optimizelegibility;-moz-appearance: optimizelegibility;appearance:= optimizelegibility;margin: 4px 0 0;color: #777777;line-height: 24px;font-s= ize: 18px;margin-top: 12px;">Most write-ups stop at “it repairs mitoc= hondria.” The actual research goes into kidneys, eyes, hearts with ge= netic disease, and a dozen other places nobody talks about.</h3><table clas= s=3D"post-meta" role=3D"presentation" width=3D"100%" border=3D"0" cellspaci= ng=3D"0" cellpadding=3D"0" style=3D"margin: 1em 0;height: 20px;align-items:= center;"><tbody><tr><td><table role=3D"presentation" width=3D"auto" border= =3D"0" cellspacing=3D"0" cellpadding=3D"0"><tbody><tr><td><table role=3D"pr= esentation" width=3D"auto" border=3D"0" cellspacing=3D"0" cellpadding=3D"0"= ><tbody><tr><td style=3D"vertical-align:middle;"><div class=3D"pencraft pc-= reset color-primary-zABazT line-height-20-t4M0El font-meta-MWBumP size-11-N= uY2Zx weight-medium-fw81nC transform-uppercase-yKDgcq reset-IxiVJZ meta-Egz= BVA custom-css-email-post-author" style=3D"list-style: none;font-size: 11px= ;line-height: 20px;text-decoration: unset;color: rgb(54,55,55);margin: 0;fo= nt-family: 'SF Compact',-apple-system,system-ui,-apple-system,BlinkMacSyste= mFont,'Segoe UI',Roboto,Helvetica,Arial,sans-serif,'Apple Color Emoji','Seg= oe UI Emoji','Segoe UI Symbol';font-weight: 500;text-transform: uppercase;l= etter-spacing: .2px;"><a class=3D"pencraft pc-reset color-primary-zABazT li= ne-height-20-t4M0El font-meta-MWBumP size-11-NuY2Zx weight-medium-fw81nC tr= ansform-uppercase-yKDgcq reset-IxiVJZ meta-EgzBVA" style=3D"list-style: non= e;color: rgb(54,55,55);margin: 0;font-size: 11px;line-height: 20px;font-fam= ily: 'SF Compact',-apple-system,system-ui,-apple-system,BlinkMacSystemFont,= 'Segoe UI',Roboto,Helvetica,Arial,sans-serif,'Apple Color Emoji','Segoe UI = Emoji','Segoe UI Symbol';font-weight: 500;text-transform: uppercase;letter-= spacing: .2px;text-decoration: none" href=3D"https://substack.com/@dereksre= searchradar">Derek</a></div></td></tr></tbody></table></td></tr><tr><td><ta= ble role=3D"presentation" width=3D"auto" border=3D"0" cellspacing=3D"0" cel= lpadding=3D"0"><tbody><tr><td style=3D"vertical-align:middle;"><div class= =3D"pencraft pc-reset color-secondary-ls1g8s line-height-20-t4M0El font-met= a-MWBumP size-11-NuY2Zx weight-medium-fw81nC transform-uppercase-yKDgcq res= et-IxiVJZ meta-EgzBVA" style=3D"list-style: none;font-size: 11px;line-heigh= t: 20px;text-decoration: unset;color: rgb(119,119,119);margin: 0;font-famil= y: 'SF Compact',-apple-system,system-ui,-apple-system,BlinkMacSystemFont,'S= egoe UI',Roboto,Helvetica,Arial,sans-serif,'Apple Color Emoji','Segoe UI Em= oji','Segoe UI Symbol';font-weight: 500;text-transform: uppercase;letter-sp= acing: .2px;"><time datetime=3D"2026-05-06T18:59:21.394Z">May 6</time></div= ></td></tr></tbody></table></td></tr></tbody></table></td><td align=3D"righ= t"><table role=3D"presentation" width=3D"auto" border=3D"0" cellspacing=3D"= 0" cellpadding=3D"0"><tbody><tr><td style=3D"vertical-align:middle;"><a hre= f=3D"https://substack.com/@dereksresearchradar"><img class=3D"custom-css-em= ail-avatar avatar-QIQ5yR" src=3D"https://substackcdn.com/image/fetch/$s_!27= SK!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-med= ia.s3.amazonaws.com%2Fpublic%2Fimages%2Ff07a8bac-9f53-43a0-af70-e96356c0f3f= 3_500x500.png" style=3D"box-sizing: border-box;max-width: 550px;border: non= e;vertical-align: middle;width: 40px;height: 40px;min-width: 40px;min-heigh= t: 40px;object-fit: cover;margin: 0px;display: inline;border-radius: 50%" w= idth=3D"40" height=3D"40"></a></td></tr></tbody></table></td></tr></tbody><= /table><table class=3D"email-ufi-2-top" role=3D"presentation" width=3D"100%= " border=3D"0" cellspacing=3D"0" cellpadding=3D"0" style=3D"border-top: 1px= solid rgb(0,0,0,.1);border-bottom: 1px solid rgb(0,0,0,.1);min-width: 100%= ;"><tbody><tr height=3D"16"><td height=3D"16" style=3D"font-size:0px;line-h= eight:0;"> </td></tr><tr><td><table role=3D"presentation" width=3D"100= %" border=3D"0" cellspacing=3D"0" cellpadding=3D"0"><tbody><tr><td><table r= ole=3D"presentation" width=3D"auto" border=3D"0" cellspacing=3D"0" cellpadd= ing=3D"0"><tbody><tr><td style=3D"vertical-align:middle;"><table role=3D"pr= esentation" width=3D"38" border=3D"0" cellspacing=3D"0" cellpadding=3D"0"><= tbody><tr><td align=3D"center"><a class=3D"email-icon-button" href=3D"https= ://substack.com/app-link/post?publication_id=3D3365367&post_id=3D196696515&= utm_source=3Dsubstack&isFreemail=3Dtrue&submitLike=3Dtrue&token=3DeyJ1c2VyX= 2lkIjoyNzM2MjIzOTgsInBvc3RfaWQiOjE5NjY5NjUxNSwicmVhY3Rpb24iOiLinaQiLCJpYXQi= OjE3NzgwOTM5OTcsImV4cCI6MTc4MDY4NTk5NywiaXNzIjoicHViLTMzNjUzNjciLCJzdWIiOiJ= yZWFjdGlvbiJ9.KUGwtV3SeozC9VW5EhuknKTHiokl8q24oZ4PXtizIAU&utm_medium=3Demai= l&utm_campaign=3Demail-reaction&r=3D4iwoe6" style=3D"font-family: system-ui= ,-apple-system,BlinkMacSystemFont,'Segoe UI',Roboto,Helvetica,Arial,sans-se= rif,'Apple Color Emoji','Segoe UI Emoji','Segoe UI Symbol';display: inline-= block;font-weight: 500;border: 1px solid rgb(0,0,0,.1);border-radius: 9999p= x;text-transform: uppercase;font-size: 12px;line-height: 1;padding: 9px 0;t= ext-decoration: none;color: rgb(119,119,119);min-width: 38px;box-sizing: bo= rder-box;width: 38px"><img class=3D"icon" src=3D"https://substackcdn.com/im= age/fetch/$s_!PeVs!,w_36,c_scale,f_png,q_auto:good,fl_progressive:steep/htt= ps%3A%2F%2Fsubstack.com%2Ficon%2FLucideHeart%3Fv%3D4%26height%3D36%26fill%3= Dnone%26stroke%3D%2523808080%26strokeWidth%3D2" width=3D"18" height=3D"18" = style=3D"border: none;vertical-align: middle;max-width: 18px" alt=3D""></a>= </td></tr></tbody></table></td><td width=3D"8" style=3D"min-width:8px;"></t= d><td style=3D"vertical-align:middle;"><table role=3D"presentation" width= =3D"38" border=3D"0" cellspacing=3D"0" cellpadding=3D"0"><tbody><tr><td ali= gn=3D"center"><a class=3D"email-icon-button" href=3D"https://substack.com/a= pp-link/post?publication_id=3D3365367&post_id=3D196696515&utm_source=3Dsubs= tack&utm_medium=3Demail&isFreemail=3Dtrue&comments=3Dtrue&token=3DeyJ1c2VyX= 2lkIjoyNzM2MjIzOTgsInBvc3RfaWQiOjE5NjY5NjUxNSwiaWF0IjoxNzc4MDkzOTk3LCJleHAi= OjE3ODA2ODU5OTcsImlzcyI6InB1Yi0zMzY1MzY3Iiwic3ViIjoicG9zdC1yZWFjdGlvbiJ9.HR= xTiWKoPv9sBLWcItbb-1Itf6pyvKSmY4q_P5Xrwl0&r=3D4iwoe6&utm_campaign=3Demail-h= alf-magic-comments&action=3Dpost-comment&utm_source=3Dsubstack&utm_medium= =3Demail" style=3D"font-family: system-ui,-apple-system,BlinkMacSystemFont,= 'Segoe UI',Roboto,Helvetica,Arial,sans-serif,'Apple Color Emoji','Segoe UI = Emoji','Segoe UI Symbol';display: inline-block;font-weight: 500;border: 1px= solid rgb(0,0,0,.1);border-radius: 9999px;text-transform: uppercase;font-s= ize: 12px;line-height: 1;padding: 9px 0;text-decoration: none;color: rgb(11= 9,119,119);min-width: 38px;box-sizing: border-box;width: 38px"><img class= =3D"icon" src=3D"https://substackcdn.com/image/fetch/$s_!x1tS!,w_36,c_scale= ,f_png,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack.com%2Ficon%2= FLucideComments%3Fv%3D4%26height%3D36%26fill%3Dnone%26stroke%3D%2523808080%= 26strokeWidth%3D2" width=3D"18" height=3D"18" style=3D"border: none;vertica= l-align: middle;max-width: 18px" alt=3D""></a></td></tr></tbody></table></t= d><td width=3D"8" style=3D"min-width:8px;"></td><td style=3D"vertical-align= :middle;"><table role=3D"presentation" width=3D"38" border=3D"0" cellspacin= g=3D"0" cellpadding=3D"0"><tbody><tr><td align=3D"center"><a class=3D"email= -icon-button" href=3D"https://substack.com/app-link/post?publication_id=3D3= 365367&post_id=3D196696515&utm_source=3Dsubstack&utm_medium=3Demail&utm_con= tent=3Dshare&utm_campaign=3Demail-share&action=3Dshare&triggerShare=3Dtrue&= isFreemail=3Dtrue&r=3D4iwoe6&token=3DeyJ1c2VyX2lkIjoyNzM2MjIzOTgsInBvc3RfaW= QiOjE5NjY5NjUxNSwiaWF0IjoxNzc4MDkzOTk3LCJleHAiOjE3ODA2ODU5OTcsImlzcyI6InB1Y= i0zMzY1MzY3Iiwic3ViIjoicG9zdC1yZWFjdGlvbiJ9.HRxTiWKoPv9sBLWcItbb-1Itf6pyvKS= mY4q_P5Xrwl0" style=3D"font-family: system-ui,-apple-system,BlinkMacSystemF= ont,'Segoe UI',Roboto,Helvetica,Arial,sans-serif,'Apple Color Emoji','Segoe= UI Emoji','Segoe UI Symbol';display: inline-block;font-weight: 500;border:= 1px solid rgb(0,0,0,.1);border-radius: 9999px;text-transform: uppercase;fo= nt-size: 12px;line-height: 1;padding: 9px 0;text-decoration: none;color: rg= b(119,119,119);min-width: 38px;box-sizing: border-box;width: 38px"><img cla= ss=3D"icon" src=3D"https://substackcdn.com/image/fetch/$s_!_L14!,w_36,c_sca= le,f_png,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack.com%2Ficon= %2FLucideShare2%3Fv%3D4%26height%3D36%26fill%3Dnone%26stroke%3D%2523808080%= 26strokeWidth%3D2" width=3D"18" height=3D"18" style=3D"border: none;vertica= l-align: middle;max-width: 18px" alt=3D""></a></td></tr></tbody></table></t= d><td width=3D"8" style=3D"min-width:8px;"></td><td style=3D"vertical-align= :middle;"><table role=3D"presentation" width=3D"38" border=3D"0" cellspacin= g=3D"0" cellpadding=3D"0"><tbody><tr><td align=3D"center"><a class=3D"email= -icon-button" href=3D"https://substack.com/redirect/2/eyJlIjoiaHR0cHM6Ly9vc= GVuLnN1YnN0YWNrLmNvbS9wdWIvZGVyZWtwcnVza2kvcC9zcy0zMS10aGUtbWl0b2Nob25kcmlh= bC1wZXB0aWRlLXdpdGg_dXRtX3NvdXJjZT1zdWJzdGFjayZ1dG1fbWVkaXVtPWVtYWlsJnV0bV9= jYW1wYWlnbj1lbWFpbC1yZXN0YWNrLWNvbW1lbnQmYWN0aW9uPXJlc3RhY2stY29tbWVudCZyPT= Rpd29lNiZ0b2tlbj1leUoxYzJWeVgybGtJam95TnpNMk1qSXpPVGdzSW5CdmMzUmZhV1FpT2pFN= U5qWTVOalV4TlN3aWFXRjBJam94TnpjNE1Ea3pPVGszTENKbGVIQWlPakUzT0RBMk9EVTVPVGNz= SW1semN5STZJbkIxWWkwek16WTFNelkzSWl3aWMzVmlJam9pY0c5emRDMXlaV0ZqZEdsdmJpSjk= uSFJ4VGlXS29QdjlzQkxXY0l0YmItMUl0ZjZweXZLU21ZNHFfUDVYcndsMCIsInAiOjE5NjY5Nj= UxNSwicyI6MzM2NTM2NywiZiI6dHJ1ZSwidSI6MjczNjIyMzk4LCJpYXQiOjE3NzgwOTM5OTcsI= mV4cCI6MjA5MzY2OTk5NywiaXNzIjoicHViLTAiLCJzdWIiOiJsaW5rLXJlZGlyZWN0In0.pszf= W7UJJ1qzAxixJDiJhNTnkoY1IinyibpJgfGGp2s?&utm_source=3Dsubstack&utm_medium= =3Demail" style=3D"font-family: system-ui,-apple-system,BlinkMacSystemFont,= 'Segoe UI',Roboto,Helvetica,Arial,sans-serif,'Apple Color Emoji','Segoe UI = Emoji','Segoe UI Symbol';display: inline-block;font-weight: 500;border: 1px= solid rgb(0,0,0,.1);border-radius: 9999px;text-transform: uppercase;font-s= ize: 12px;line-height: 1;padding: 9px 0;text-decoration: none;color: rgb(11= 9,119,119);min-width: 38px;box-sizing: border-box;width: 38px"><img class= =3D"icon" src=3D"https://substackcdn.com/image/fetch/$s_!ubXF!,w_36,c_scale= ,f_png,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack.com%2Ficon%2= Fnotes__NoteRestackIcon%3Fv%3D4%26height%3D36%26fill%3Dnone%26stroke%3D%252= 3808080%26strokeWidth%3D2%26strokeLinecap%3Dround%26strokeLinejoin%3Dround"= width=3D"18" height=3D"18" alt=3D"" style=3D"max-width: 550px;border: none= !important;vertical-align: middle;"></a></td></tr></tbody></table></td></t= r></tbody></table></td><td align=3D"right"><table role=3D"presentation" wid= th=3D"auto" border=3D"0" cellspacing=3D"0" cellpadding=3D"0"><tbody><tr><td= style=3D"vertical-align:middle;"><table role=3D"presentation" width=3D"aut= o" border=3D"0" cellspacing=3D"0" cellpadding=3D"0"><tbody><tr><td align=3D= "center"><a class=3D"email-button-outline" href=3D"https://open.substack.co= m/pub/derekpruski/p/ss-31-the-mitochondrial-peptide-with?utm_source=3Demail= &redirect=3Dapp-store&utm_campaign=3Demail-read-in-app" style=3D"font-famil= y: system-ui,-apple-system,BlinkMacSystemFont,'Segoe UI',Roboto,Helvetica,A= rial,sans-serif,'Apple Color Emoji','Segoe UI Emoji','Segoe UI Symbol';disp= lay: inline-block;font-weight: 500;border: 1px solid rgb(0,0,0,.1);border-r= adius: 9999px;text-transform: uppercase;font-size: 12px;line-height: 12px;p= adding: 9px 14px;text-decoration: none;color: rgb(119,119,119);"><div class= =3D"email-button-spacer" style=3D"font-size: 16px;line-height: 26px;display= : inline-block;vertical-align: middle;max-width: 0;min-height: 18px;"></div= ><span class=3D"email-button-text" style=3D"vertical-align: middle;margin-r= ight: 4px">READ IN APP</span><img class=3D"icon text-icon" src=3D"https://s= ubstackcdn.com/image/fetch/$s_!ET-_!,w_36,c_scale,f_png,q_auto:good,fl_prog= ressive:steep/https%3A%2F%2Fsubstack.com%2Ficon%2FLucideArrowUpRight%3Fv%3D= 4%26height%3D36%26fill%3Dnone%26stroke%3D%2523808080%26strokeWidth%3D2" wid= th=3D"18" height=3D"18" style=3D"min-width: 18px;min-height: 18px;border: n= one;vertical-align: middle;margin-right: 0;margin-left: 0;max-width: 18px" = alt=3D""></a></td></tr></tbody></table></td></tr></tbody></table></td></tr>= </tbody></table></td></tr><tr height=3D"16"><td height=3D"16" style=3D"font= -size:0px;line-height:0;"> </td></tr></tbody></table></div></div><div = class=3D"post typography" dir=3D"auto" style=3D"--image-offset-margin: -120= px;padding: 32px 0 0 0;font-size: 16px;line-height: 26px;"><div class=3D"bo= dy markup" dir=3D"auto" style=3D"text-align: initial;font-size: 16px;line-h= eight: 26px;width: 100%;word-break: break-word;margin-bottom: 16px;"><p sty= le=3D"margin: 0 0 20px 0;color: rgb(54,55,55);line-height: 26px;font-size: = 16px;margin-top: 0;"><em>Research and educational purposes only. Nothing in= this piece is medical advice. If you’re considering anything persona= lly, that’s a conversation for a qualified clinician.</em></p><div st= yle=3D"font-size: 16px;line-height: 26px;"><hr style=3D"margin: 32px 0;padd= ing: 0;height: 1px;background: rgb(0,0,0,.1);border: none;"></div><p style= =3D"margin: 0 0 20px 0;color: rgb(54,55,55);line-height: 26px;font-size: 16= px;"><span>Most of the SS-31 conversation in the peptide world stops at one= sentence: </span><em>“it repairs mitochondria.”</em><span> And= that’s true — but it massively undersells what this peptide ac= tually does and where it’s been studied.</span></p><div class=3D"capt= ioned-image-container-static" style=3D"font-size: 16px;line-height: 26px;ma= rgin: 32px auto;"><figure style=3D"width: 100%;margin: 0 auto;"><table clas= s=3D"image-wrapper" width=3D"100%" border=3D"0" cellspacing=3D"0" cellpaddi= ng=3D"0" data-component-name=3D"Image2ToDOMStatic" style=3D"mso-padding-alt= : 1em 0 1.6em;"><tbody><tr><td style=3D"text-align: center;"></td><td class= =3D"content" align=3D"left" width=3D"1181" style=3D"text-align: center;"><a= class=3D"image-link" target=3D"_blank" href=3D"https://substack.com/redire= ct/c9206a31-35aa-4441-9572-f402e0f83d8b?j=3DeyJ1IjoiNGl3b2U2In0.sVDxRtmZ85v= 8kfdamY0krRXGMy3p768BWtuZifRB-Zs" style=3D"position: relative;flex-directio= n: column;align-items: center;padding: 0;width: auto;height: auto;border: n= one;text-decoration: none;display: block;margin: 0;"><img class=3D"wide-ima= ge" data-attrs=3D"{"src":"https://substack-post-media.s3.ama= zonaws.com/public/images/2ab09f9f-ac70-4c8d-9cb6-0e10856288b2_1181x1331.png= ","srcNoWatermark":null,"fullscreen":null,"im= ageSize":null,"height":1331,"width":1181,"res= izeWidth":null,"bytes":2315142,"alt":null,"ti= tle":null,"type":"image/png","href":null= ,"belowTheFold":false,"topImage":true,"internalRed= irect":"https://derekpruski.substack.com/i/196696515?img=3Dhttps%= 3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F2ab09f9f-a= c70-4c8d-9cb6-0e10856288b2_1181x1331.png","isProcessing":fal= se,"align":null,"offset":false}" alt=3D"" width=3D"550"= height=3D"619.8560541913632" src=3D"https://substackcdn.com/image/fetch/$s= _!dX5C!,w_1100,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%= 2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F2ab09f9f-ac70-4c= 8d-9cb6-0e10856288b2_1181x1331.png" style=3D"border: none !important;vertic= al-align: middle;display: block;-ms-interpolation-mode: bicubic;height: aut= o;margin-bottom: 0;width: auto !important;max-width: 100% !important;margin= : 0 auto;"></a></td><td style=3D"text-align: center;"></td></tr></tbody></t= able></figure></div><p style=3D"margin: 0 0 20px 0;color: rgb(54,55,55);lin= e-height: 26px;font-size: 16px;">When you start digging through the literat= ure, SS-31 has clinical trial data in places you probably wouldn’t ex= pect. Kidney disease. Macular degeneration. Heart failure. Barth syndrome. = Glaucoma. Hearing loss. Diabetic complications. Some of the most interestin= g research isn’t about energy or aging in a generic sense — it&= #8217;s about specific organ systems that people don’t usually associ= ate with mitochondrial peptides.</p><p style=3D"margin: 0 0 20px 0;color: r= gb(54,55,55);line-height: 26px;font-size: 16px;">This piece walks through w= hat SS-31 is, hits the mitochondrial mechanism quickly so we have a foundat= ion, and then spends most of the time on the applications nobody talks abou= t.</p><div class=3D"subscribe-widget is-signed-up" data-component-name=3D"S= ubscribeWidget" style=3D"margin: 0 0 1em;direction: ltr;font-size: 16px;lin= e-height: 26px;"><div class=3D"pencraft pc-reset button-wrapper" style=3D"t= ext-decoration: unset;list-style: none;font-size: 16px;line-height: 26px;te= xt-align: center;cursor: pointer;border-radius: 4px;"><a class=3D"button su= bscribe-btn primary" href=3D"https://substack.com/redirect/2/eyJlIjoiaHR0cH= M6Ly9kZXJla3BydXNraS5zdWJzdGFjay5jb20vc3Vic2NyaWJlP3V0bV9zb3VyY2U9cG9zdCZ1d= G1fY2FtcGFpZ249ZW1haWwtY2hlY2tvdXQmbmV4dD1odHRwcyUzQSUyRiUyRmRlcmVrcHJ1c2tp= LnN1YnN0YWNrLmNvbSUyRnAlMkZzcy0zMS10aGUtbWl0b2Nob25kcmlhbC1wZXB0aWRlLXdpdGg= mcj00aXdvZTYmdG9rZW49ZXlKMWMyVnlYMmxrSWpveU56TTJNakl6T1Rnc0ltbGhkQ0k2TVRjM0= 9EQTVNems1Tnl3aVpYaHdJam94Tnpnd05qZzFPVGszTENKcGMzTWlPaUp3ZFdJdE16TTJOVE0yT= nlJc0luTjFZaUk2SW1Ob1pXTnJiM1YwSW4wLmdYMEZMUTQwUnNwS2thSnZYMy1qWG82WmFWYTBI= cU9ONmJUaW5fMENsUEkiLCJwIjoxOTY2OTY1MTUsInMiOjMzNjUzNjcsImYiOnRydWUsInUiOjI= 3MzYyMjM5OCwiaWF0IjoxNzc4MDkzOTk3LCJleHAiOjIwOTM2Njk5OTcsImlzcyI6InB1Yi0wIi= wic3ViIjoibGluay1yZWRpcmVjdCJ9.vAoG2YIG3O1lctAzIBkyi0gzj8iuBwyzBdqvfas3hGg?= &utm_medium=3Demail&utm_source=3Dsubscribe-widget&utm_content=3D196696515" = style=3D"font-family: system-ui,-apple-system,BlinkMacSystemFont,'Segoe UI'= ,Roboto,Helvetica,Arial,sans-serif,'Apple Color Emoji','Segoe UI Emoji','Se= goe UI Symbol';display: inline-block;box-sizing: border-box;cursor: pointer= ;border: none;border-radius: 8px;font-size: 14px;line-height: 20px;font-wei= ght: 600;text-align: center;opacity: 1;outline: none;white-space: nowrap;te= xt-decoration: none !important;margin: 0 auto;background-color: #FF6719;col= or: #ffffff !important;padding: 12px 20px;height: auto;"><span style=3D"col= or: #ffffff;text-decoration: none;">Upgrade to paid</span></a></div></div><= h2 class=3D"header-anchor-post" style=3D"position: relative;font-family: 'S= F Pro Display',-apple-system-headline,system-ui,-apple-system,BlinkMacSyste= mFont,'Segoe UI',Roboto,Helvetica,Arial,sans-serif,'Apple Color Emoji','Seg= oe UI Emoji','Segoe UI Symbol';font-weight: bold;-webkit-font-smoothing: an= tialiased;-moz-osx-font-smoothing: antialiased;-webkit-appearance: optimize= legibility;-moz-appearance: optimizelegibility;appearance: optimizelegibili= ty;margin: 1em 0 0.625em 0;color: rgb(54,55,55);line-height: 1.16em;font-si= ze: calc(1.625em * 1);">What SS-31 Actually Is (The Quick Version)</h2><p s= tyle=3D"margin: 0 0 20px 0;color: rgb(54,55,55);line-height: 26px;font-size= : 16px;"><span>SS-31 — also called </span><strong>elamipretide</stron= g><span>, </span><strong>MTP-131</strong><span>, and </span><strong>Bendavi= a</strong><span> in different research contexts — is a synthetic tetr= apeptide. Four amino acids, no more. It was discovered by Dr. Hazel Szeto a= t Weill Cornell Medical College, hence the “SS” naming.</span><= /p><p style=3D"margin: 0 0 20px 0;color: rgb(54,55,55);line-height: 26px;fo= nt-size: 16px;">What makes it unique:</p><blockquote style=3D"border-left: = 4px solid #FF6719;margin: 20px 0;padding: 0;"><p style=3D"margin: 0 0 20px = 0;color: rgb(54,55,55);margin-left: 20px;line-height: 26px;font-size: 16px;= ">SS-31 doesn’t just float around the cell. It selectively concentrat= es inside the inner mitochondrial membrane at concentrations 1,000 to 5,000= times higher than the surrounding tissue.</p></blockquote><p style=3D"marg= in: 0 0 20px 0;color: rgb(54,55,55);line-height: 26px;font-size: 16px;">Tha= t kind of targeting precision is rare for any compound, let alone a peptide= =2E</p><p style=3D"margin: 0 0 20px 0;co= lor: rgb(54,55,55);line-height: 26px;= font-size: 16px;"><span>Once it gets there, it binds to a phospholipid call= ed </span><strong>cardiolipin</strong><span> — the structural backbon= e of the inner mitochondrial membrane. Cardiolipin is what holds the crista= e (the folded inner structure of the mitochondria) in place, and it’s= required for the electron transport chain to assemble properly. When cardi= olipin gets damaged or oxidized, mitochondria literally fall apart from the= inside.</span></p><p style=3D"margin: 0 0 20px 0;color: rgb(54,55,55);line= -height: 26px;font-size: 16px;">SS-31 protects cardiolipin from peroxidatio= n and stabilizes the membrane structure. Net result: mitochondria stop leak= ing, ATP production goes back up, ROS drops, and cells stop dying from ener= gy failure.</p><p style=3D"margin: 0 0 20px 0;color: rgb(54,55,55);line-hei= ght: 26px;font-size: 16px;">That’s the headline mechanism. Now the st= uff people don’t talk about enough.</p><h2 class=3D"header-anchor-pos= t" style=3D"position: relative;font-family: 'SF Pro Display',-apple-system-= headline,system-ui,-apple-system,BlinkMacSystemFont,'Segoe UI',Roboto,Helve= tica,Arial,sans-serif,'Apple Color Emoji','Segoe UI Emoji','Segoe UI Symbol= ';font-weight: bold;-webkit-font-smoothing: antialiased;-moz-osx-font-smoot= hing: antialiased;-webkit-appearance: optimizelegibility;-moz-appearance: o= ptimizelegibility;appearance: optimizelegibility;margin: 1em 0 0.625em 0;co= lor: rgb(54,55,55);line-height: 1.16em;font-size: calc(1.625em * 1);">The K= idney Story</h2><p style=3D"margin: 0 0 20px 0;color: rgb(54,55,55);line-he= ight: 26px;font-size: 16px;">This is one of the most underrated areas of SS= -31 research, and it makes total sense once you understand the kidney’= ;s biology.</p><p style=3D"margin: 0 0 20px 0;color: rgb(54,55,55);line-hei= ght: 26px;font-size: 16px;"><strong>Why kidneys are mitochondria-dependent.= </strong><span> The kidney is one of the most metabolically demanding organ= s in the body. Specifically, the proximal tubules — the part of the n= ephron responsible for reabsorbing nutrients, electrolytes, and water back = into the bloodstream — are packed with mitochondria. They have to be,= because reabsorption is an active transport process that requires enormous= amounts of ATP. </span><em>When mitochondria fail in the kidney, the kidne= y fails.</em></p><p style=3D"margin: 0 0 20px 0;color: rgb(54,55,55);line-h= eight: 26px;font-size: 16px;"><strong>What the research shows.</strong><spa= n> SS-31 has been studied across nearly every category of kidney disease in= research models — acute kidney injury, ischemia-reperfusion injury (= the damage that happens when blood flow returns to a tissue after being cut= off), diabetic nephropathy, polycystic kidney disease, atherosclerotic ren= al artery stenosis, and aging-related kidney decline.</span></p><p style=3D= "margin: 0 0 20px 0;color: rgb(54,55,55);line-height: 26px;font-size: 16px;= "><strong>The atherosclerotic renal artery stenosis trial.</strong><span> T= his one is worth pulling out specifically. In a Phase 2a clinical trial, pa= tients undergoing stent revascularization for atherosclerotic renal artery = stenosis received SS-31 infusions. The peptide was well tolerated with no s= erious adverse events. More importantly, the research showed measurable imp= rovements in renal blood flow and oxygenation in the affected kidneys. </sp= an><em>This is real human data in a serious, late-stage kidney condition.</= em></p><p style=3D"margin: 0 0 20px 0;color: rgb(54,55,55);line-height: 26p= x;font-size: 16px;"><strong>The mechanism in kidneys.</strong><span> SS-31 = reduces tubular cell apoptosis (cells dying from energy failure), reduces f= ibrosis (scarring that progressively destroys kidney function), and preserv= es mitochondrial structure in the proximal tubules. In aging research, it&#= 8217;s been shown to reverse some age-related decline in kidney function in= animal models.</span></p><p style=3D"margin: 0 0 20px 0;color: rgb(54,55,5= 5);line-height: 26px;font-size: 16px;">For anyone interested in longevity f= rom a “preserve organ function” angle, the kidneys are usually = one of the first places to start failing in older populations. SS-31 might = be one of the most direct mitochondrial tools available for that exact prob= lem.</p><h2 class=3D"header-anchor-post" style=3D"position: relative;font-f= amily: 'SF Pro Display',-apple-system-headline,system-ui,-apple-system,Blin= kMacSystemFont,'Segoe UI',Roboto,Helvetica,Arial,sans-serif,'Apple Color Em= oji','Segoe UI Emoji','Segoe UI Symbol';font-weight: bold;-webkit-font-smoo= thing: antialiased;-moz-osx-font-smoothing: antialiased;-webkit-appearance:= optimizelegibility;-moz-appearance: optimizelegibility;appearance: optimiz= elegibility;margin: 1em 0 0.625em 0;color: rgb(54,55,55);line-height: 1.16e= m;font-size: calc(1.625em * 1);">The Eye Story</h2><p style=3D"margin: 0 0 = 20px 0;color: rgb(54,55,55);line-height: 26px;font-size: 16px;">This is the= one almost nobody knows about, and it might be the most clinically advance= d application of SS-31 in humans.</p><p style=3D"margin: 0 0 20px 0;color: = rgb(54,55,55);line-height: 26px;font-size: 16px;"><strong>Why eyes are mito= chondrial.</strong><span> The retina — specifically the photoreceptor= s and the retinal pigment epithelium (RPE) — has one of the highest m= itochondrial densities of any tissue in the body. Vision is metabolically e= xpensive. Every time a photon hits a photoreceptor, mitochondria have to fi= re to convert that signal into something the brain can read. As mitochondri= a age, the photoreceptors start dying, and you get age-related macular dege= neration (AMD).</span></p><h3 class=3D"header-anchor-post" style=3D"positio= n: relative;font-family: 'SF Pro Display',-apple-system-headline,system-ui,= -apple-system,BlinkMacSystemFont,'Segoe UI',Roboto,Helvetica,Arial,sans-ser= if,'Apple Color Emoji','Segoe UI Emoji','Segoe UI Symbol';font-weight: bold= ;-webkit-font-smoothing: antialiased;-moz-osx-font-smoothing: antialiased;-= webkit-appearance: optimizelegibility;-moz-appearance: optimizelegibility;a= ppearance: optimizelegibility;margin: 1em 0 0.625em 0;color: rgb(54,55,55);= line-height: 1.16em;font-size: calc(1.375em * 1);">The ReCLAIM trials</h3><= p style=3D"margin: 0 0 20px 0;color: rgb(54,55,55);line-height: 26px;font-s= ize: 16px;">SS-31 has been studied in a series of clinical trials for dry A= MD with noncentral geographic atrophy — the early-to-intermediate for= m of the leading cause of irreversible blindness in people over 50. These t= rials are called ReCLAIM and ReCLAIM-2, and they’ve been running thro= ugh Phase 1 and Phase 2.</p><p style=3D"margin: 0 0 20px 0;color: rgb(54,55= ,55);line-height: 26px;font-size: 16px;">Patients received subcutaneous SS-= 31 at 40 mg daily for 24 to 48 weeks. The trials demonstrated:</p><ul style= =3D"margin-top: 0;padding: 0;"><li style=3D"margin: 8px 0 0 32px;mso-specia= l-format: bullet;"><p style=3D"color: rgb(54,55,55);line-height: 26px;margi= n-bottom: 0;box-sizing: border-box;padding-left: 4px;font-size: 16px;margin= : 0;">Good safety and tolerability</p></li><li style=3D"margin: 8px 0 0 32p= x;mso-special-format: bullet;"><p style=3D"color: rgb(54,55,55);line-height= : 26px;margin-bottom: 0;box-sizing: border-box;padding-left: 4px;font-size:= 16px;margin: 0;">Positive effects on visual function, particularly under l= ow-luminance conditions (one of the first things to go in early AMD)</p></l= i><li style=3D"margin: 8px 0 0 32px;mso-special-format: bullet;"><p style= =3D"color: rgb(54,55,55);line-height: 26px;margin-bottom: 0;box-sizing: bor= der-box;padding-left: 4px;font-size: 16px;margin: 0;">Preservation of ellip= soid zone integrity (a marker of photoreceptor health on retinal imaging)</= p></li></ul><h3 class=3D"header-anchor-post" style=3D"position: relative;fo= nt-family: 'SF Pro Display',-apple-system-headline,system-ui,-apple-system,= BlinkMacSystemFont,'Segoe UI',Roboto,Helvetica,Arial,sans-serif,'Apple Colo= r Emoji','Segoe UI Emoji','Segoe UI Symbol';font-weight: bold;-webkit-font-= smoothing: antialiased;-moz-osx-font-smoothing: antialiased;-webkit-appeara= nce: optimizelegibility;-moz-appearance: optimizelegibility;appearance: opt= imizelegibility;margin: 1em 0 0.625em 0;color: rgb(54,55,55);line-height: 1= =2E16em;font-size: calc(1.375em * 1);"= >Currently in Phase 3</h3><p style=3D"m= argin: 0 0 20px 0;color: rgb(54,55,55);line-height: 26px;font-size: 16px;">= <span>As of 2025, Stealth BioTherapeutics has Phase 3 trials running —= ; </span><strong>ReNEW</strong><span> and </span><strong>ReGAIN</strong><sp= an> — with 360 patients each, evaluating SS-31 specifically for dry A= MD. This is genuinely advanced clinical development for a peptide.</span></= p><h3 class=3D"header-anchor-post" style=3D"position: relative;font-family:= 'SF Pro Display',-apple-system-headline,system-ui,-apple-system,BlinkMacSy= stemFont,'Segoe UI',Roboto,Helvetica,Arial,sans-serif,'Apple Color Emoji','= Segoe UI Emoji','Segoe UI Symbol';font-weight: bold;-webkit-font-smoothing:= antialiased;-moz-osx-font-smoothing: antialiased;-webkit-appearance: optim= izelegibility;-moz-appearance: optimizelegibility;appearance: optimizelegib= ility;margin: 1em 0 0.625em 0;color: rgb(54,55,55);line-height: 1.16em;font= -size: calc(1.375em * 1);">Beyond AMD</h3><p style=3D"margin: 0 0 20px 0;co= lor: rgb(54,55,55);line-height: 26px;font-size: 16px;">Preclinical research= has also shown effects on glaucoma (where retinal ganglion cells die from = mitochondrial dysfunction in the optic nerve), diabetic retinopathy, and dr= y eye disease. The eye is mitochondria-dense, and SS-31 keeps showing up wh= erever mitochondria are the bottleneck.</p><p style=3D"margin: 0 0 20px 0;c= olor: rgb(54,55,55);line-height: 26px;font-size: 16px;">If you have family = history of macular degeneration or you’re already noticing low-light = vision changes, this is an area of the literature worth understanding deepl= y.</p><h2 class=3D"header-anchor-post" style=3D"position: relative;font-fam= ily: 'SF Pro Display',-apple-system-headline,system-ui,-apple-system,BlinkM= acSystemFont,'Segoe UI',Roboto,Helvetica,Arial,sans-serif,'Apple Color Emoj= i','Segoe UI Emoji','Segoe UI Symbol';font-weight: bold;-webkit-font-smooth= ing: antialiased;-moz-osx-font-smoothing: antialiased;-webkit-appearance: o= ptimizelegibility;-moz-appearance: optimizelegibility;appearance: optimizel= egibility;margin: 1em 0 0.625em 0;color: rgb(54,55,55);line-height: 1.16em;= font-size: calc(1.625em * 1);">The Heart Story (Beyond Generic “Cardi= oprotection”)</h2><p style=3D"margin: 0 0 20px 0;color: rgb(54,55,55)= ;line-height: 26px;font-size: 16px;">I’m including this because most = people who hear “SS-31 helps the heart” assume it’s just = generic cardioprotection. The actual research is more specific and more int= eresting.</p><h3 class=3D"header-anchor-post" style=3D"position: relative;f= ont-family: 'SF Pro Display',-apple-system-headline,system-ui,-apple-system= ,BlinkMacSystemFont,'Segoe UI',Roboto,Helvetica,Arial,sans-serif,'Apple Col= or Emoji','Segoe UI Emoji','Segoe UI Symbol';font-weight: bold;-webkit-font= -smoothing: antialiased;-moz-osx-font-smoothing: antialiased;-webkit-appear= ance: optimizelegibility;-moz-appearance: optimizelegibility;appearance: op= timizelegibility;margin: 1em 0 0.625em 0;color: rgb(54,55,55);line-height: = 1.16em;font-size: calc(1.375em * 1);">Barth syndrome</h3><p style=3D"margin= : 0 0 20px 0;color: rgb(54,55,55);line-height: 26px;font-size: 16px;">This = is a rare X-linked genetic disease where boys are born with a defect in the= TAZ gene, which makes the enzyme responsible for properly maturing cardiol= ipin. Without functional cardiolipin, their mitochondria — especially= in the heart — can’t form proper cristae structure. They devel= op severe cardiomyopathy and skeletal muscle weakness, often in infancy.</p= ><p style=3D"margin: 0 0 20px 0;color: rgb(54,55,55);line-height: 26px;font= -size: 16px;"><span>SS-31 was tested in Barth syndrome patients in the </sp= an><strong>TAZPOWER</strong><span> trial and its open-label extension. Long= -term treatment (48 weeks) showed significant improvements in:</span></p><u= l style=3D"margin-top: 0;padding: 0;"><li style=3D"margin: 8px 0 0 32px;mso= -special-format: bullet;"><p style=3D"color: rgb(54,55,55);line-height: 26p= x;margin-bottom: 0;box-sizing: border-box;padding-left: 4px;font-size: 16px= ;margin: 0;">6-minute walk test performance</p></li><li style=3D"margin: 8p= x 0 0 32px;mso-special-format: bullet;"><p style=3D"color: rgb(54,55,55);li= ne-height: 26px;margin-bottom: 0;box-sizing: border-box;padding-left: 4px;f= ont-size: 16px;margin: 0;">Cardiac stroke volume</p></li><li style=3D"margi= n: 8px 0 0 32px;mso-special-format: bullet;"><p style=3D"color: rgb(54,55,5= 5);line-height: 26px;margin-bottom: 0;box-sizing: border-box;padding-left: = 4px;font-size: 16px;margin: 0;">Barth Syndrome Symptom Assessment scores</p= ></li></ul><p style=3D"margin: 0 0 20px 0;color: rgb(54,55,55);line-height:= 26px;font-size: 16px;"><span>SS-31 received orphan drug designation for Ba= rth syndrome and is now FDA-approved as </span><strong>Forzinity</strong><s= pan> — making it one of the very few peptides to make it through to a= ctual approval.</span></p><h3 class=3D"header-anchor-post" style=3D"positio= n: relative;font-family: 'SF Pro Display',-apple-system-headline,system-ui,= -apple-system,BlinkMacSystemFont,'Segoe UI',Roboto,Helvetica,Arial,sans-ser= if,'Apple Color Emoji','Segoe UI Emoji','Segoe UI Symbol';font-weight: bold= ;-webkit-font-smoothing: antialiased;-moz-osx-font-smoothing: antialiased;-= webkit-appearance: optimizelegibility;-moz-appearance: optimizelegibility;a= ppearance: optimizelegibility;margin: 1em 0 0.625em 0;color: rgb(54,55,55);= line-height: 1.16em;font-size: calc(1.375em * 1);">HFpEF (heart failure wit= h preserved ejection fraction)</h3><p style=3D"margin: 0 0 20px 0;color: rg= b(54,55,55);line-height: 26px;font-size: 16px;">This is the heart failure t= ype that’s notoriously difficult to treat. SS-31 has been studied her= e too, with mixed results — improvements in mitochondrial bioenergeti= cs measured at the molecular level, but the functional cardiac improvements= haven’t always translated. The PROGRESS-HF trial is ongoing.</p><p s= tyle=3D"margin: 0 0 20px 0;color: rgb(54,55,55);line-height: 26px;font-size= : 16px;"><strong>The honest take:</strong><span> SS-31 has the strongest ca= rdiac evidence in genetic cardiolipin deficiency (Barth) and demonstrable m= itochondrial heart disease. The general “I want to protect my heart&#= 8221; use case has weaker evidence than the specific “my mitochondria= are failing in my heart muscle” use case. Important distinction.</sp= an></p><h2 class=3D"header-anchor-post" style=3D"position: relative;font-fa= mily: 'SF Pro Display',-apple-system-headline,system-ui,-apple-system,Blink= MacSystemFont,'Segoe UI',Roboto,Helvetica,Arial,sans-serif,'Apple Color Emo= ji','Segoe UI Emoji','Segoe UI Symbol';font-weight: bold;-webkit-font-smoot= hing: antialiased;-moz-osx-font-smoothing: antialiased;-webkit-appearance: = optimizelegibility;-moz-appearance: optimizelegibility;appearance: optimize= legibility;margin: 1em 0 0.625em 0;color: rgb(54,55,55);line-height: 1.16em= ;font-size: calc(1.625em * 1);">The Neuroprotection Angle</h2><p style=3D"m= argin: 0 0 20px 0;color: rgb(54,55,55);line-height: 26px;font-size: 16px;">= The brain is mitochondria-heavy, and SS-31 crosses the blood-brain barrier = — though brain concentrations are lower than what you see in kidney, = heart, and skeletal muscle.</p><p style=3D"margin: 0 0 20px 0;color: rgb(54= ,55,55);line-height: 26px;font-size: 16px;"><strong>Alzheimer’s disea= se (preclinical).</strong><span> In AD mouse models, SS-31 has been shown t= o reduce amyloid-beta accumulation, protect synaptic function, reduce neuro= inflammation, and preserve cognitive performance. The mechanism is what you= ’d expect — neurons in AD brains have failing mitochondria, and= SS-31 stabilizes them before the cells die.</span></p><p style=3D"margin: = 0 0 20px 0;color: rgb(54,55,55);line-height: 26px;font-size: 16px;"><strong= >Parkinson’s disease (preclinical).</strong><span> Dopaminergic neuro= ns are extremely mitochondria-dependent. SS-31 protected dopaminergic neuro= ns in MPTP-induced PD models in mice and reduced motor deficits.</span></p>= <p style=3D"margin: 0 0 20px 0;color: rgb(54,55,55);line-height: 26px;font-= size: 16px;"><strong>Stroke and TBI.</strong><span> After a stroke or traum= atic brain injury, the brain accumulates oxidative stress that causes secon= dary damage. SS-31 has shown protection against this secondary injury phase= in animal models.</span></p><p style=3D"margin: 0 0 20px 0;color: rgb(54,5= 5,55);line-height: 26px;font-size: 16px;"><strong>Anesthesia-induced cognit= ive decline.</strong><span> There’s a specific area of research on po= st-operative cognitive dysfunction in older patients exposed to anesthesia = like isoflurane. SS-31 prevented the cognitive deficits in aged mice and pr= eserved hippocampal mitochondrial function. Niche, but interesting if you k= now anyone facing major surgery in older age.</span></p><blockquote style= =3D"border-left: 4px solid #FF6719;margin: 20px 0;padding: 0;"><p style=3D"= margin: 0 0 20px 0;color: rgb(54,55,55);margin-left: 20px;line-height: 26px= ;font-size: 16px;">Important caveat: almost all CNS data is preclinical. Th= ere’s no completed Phase 2 or Phase 3 SS-31 trial in Alzheimer’= s or Parkinson’s specifically, and the brain concentrations achieved = with subcutaneous dosing are lower than other tissues. Use this section as = a “promising direction” rather than “established outcome.= ”</p></blockquote><h2 class=3D"header-anchor-post" style=3D"position:= relative;font-family: 'SF Pro Display',-apple-system-headline,system-ui,-a= pple-system,BlinkMacSystemFont,'Segoe UI',Roboto,Helvetica,Arial,sans-serif= ,'Apple Color Emoji','Segoe UI Emoji','Segoe UI Symbol';font-weight: bold;-= webkit-font-smoothing: antialiased;-moz-osx-font-smoothing: antialiased;-we= bkit-appearance: optimizelegibility;-moz-appearance: optimizelegibility;app= earance: optimizelegibility;margin: 1em 0 0.625em 0;color: rgb(54,55,55);li= ne-height: 1.16em;font-size: calc(1.625em * 1);">The Less-Discussed Applica= tions</h2><p style=3D"margin: 0 0 20px 0;color: rgb(54,55,55);line-height: = 26px;font-size: 16px;">A quick rundown of areas where SS-31 has preclinical= research that almost never gets talked about:</p><p style=3D"margin: 0 0 2= 0px 0;color: rgb(54,55,55);line-height: 26px;font-size: 16px;"><strong>Hear= ing loss.</strong><span> SS-31 has been studied for noise-induced and age-r= elated hearing loss. Hair cells in the cochlea are mitochondria-rich and di= e from oxidative damage. SS-31 protected them in animal models of noise exp= osure.</span></p><p style=3D"margin: 0 0 20px 0;color: rgb(54,55,55);line-h= eight: 26px;font-size: 16px;"><strong>Diabetic complications.</strong><span= > Beyond diabetic nephropathy and retinopathy mentioned above, SS-31 has be= en studied in diabetic cardiomyopathy and peripheral nerve damage. The comm= on thread: high glucose damages mitochondria across multiple tissues, and S= S-31 protects them.</span></p><p style=3D"margin: 0 0 20px 0;color: rgb(54,= 55,55);line-height: 26px;font-size: 16px;"><strong>Osteoarthritis.</strong>= <span> Cartilage cells (chondrocytes) have failing mitochondria in OA, and = SS-31 has shown chondroprotective effects in animal models.</span></p><p st= yle=3D"margin: 0 0 20px 0;color: rgb(54,55,55);line-height: 26px;font-size:= 16px;"><strong>Skin aging.</strong><span> Some early research on SS-31 and= skin elasticity, photoaging protection, and wound healing — though m= ost of this is in vitro or in animal models, not human trials.</span></p><p= style=3D"margin: 0 0 20px 0;color: rgb(54,55,55);line-height: 26px;font-si= ze: 16px;"><strong>Skeletal muscle aging (sarcopenia).</strong><span> In ag= ed mice, SS-31 restored ATP production in skeletal muscle within roughly an= hour of administration, improved exercise tolerance, and increased muscle = mass over longer treatment periods. The MOTS-c-style use case overlaps here= , but SS-31 works on a different mechanism (membrane stabilization vs. meta= bolic signaling).</span></p><p style=3D"margin: 0 0 20px 0;color: rgb(54,55= ,55);line-height: 26px;font-size: 16px;"><strong>Sepsis and ischemia-reperf= usion injury.</strong><span> In critical care research models, SS-31 has sh= own protection against multi-organ failure driven by mitochondrial collapse= =2E</span></p><h2 class=3D"header-ancho= r-post" style=3D"position: relative;fo= nt-family: 'SF Pro Display',-apple-system-headline,system-ui,-apple-system,= BlinkMacSystemFont,'Segoe UI',Roboto,Helvetica,Arial,sans-serif,'Apple Colo= r Emoji','Segoe UI Emoji','Segoe UI Symbol';font-weight: bold;-webkit-font-= smoothing: antialiased;-moz-osx-font-smoothing: antialiased;-webkit-appeara= nce: optimizelegibility;-moz-appearance: optimizelegibility;appearance: opt= imizelegibility;margin: 1em 0 0.625em 0;color: rgb(54,55,55);line-height: 1= =2E16em;font-size: calc(1.625em * 1);">= The Honest Take on SS-31</h2><p style= =3D"margin: 0 0 20px 0;color: rgb(54,55,55);line-height: 26px;font-size: 16= px;">A few things that don’t get said enough.</p><p style=3D"margin: = 0 0 20px 0;color: rgb(54,55,55);line-height: 26px;font-size: 16px;"><strong= >It’s one of the only peptides with serious human clinical trial data= =2E</strong><span> Most peptides we tal= k about have preclinical research and=20= anecdotal protocols. SS-31 has Phase 2 and Phase 3 trials across multiple i= ndications, FDA approval in Barth syndrome (as Forzinity), and a pharmaceut= ical company (Stealth BioTherapeutics) running a full development pipeline = behind it.</span></p><p style=3D"margin: 0 0 20px 0;color: rgb(54,55,55);li= ne-height: 26px;font-size: 16px;"><strong>Not every trial has been a win.</= strong><span> The MMPOWER-3 trial in primary mitochondrial myopathy missed = its primary endpoint of 6-minute walk test improvement, though patients rep= orted less fatigue. Some HFpEF and HFrEF trials have shown molecular improv= ements without translating to functional cardiac changes. The compound isn&= #8217;t a cure-all, and the literature reflects that honestly.</span></p><p= style=3D"margin: 0 0 20px 0;color: rgb(54,55,55);line-height: 26px;font-si= ze: 16px;"><strong>It works best where mitochondria are the bottleneck.</st= rong><span> SS-31 is a precision tool, not a generic “feel betterR= 21; peptide. In conditions where mitochondrial dysfunction is genuinely the= upstream driver — Barth syndrome, certain kidney injuries, dry AMD, = mitochondrial disease — the effects are real. In conditions where mit= ochondria are downstream of bigger problems, SS-31 can support but won̵= 7;t reverse the underlying issue.</span></p><p style=3D"margin: 0 0 20px 0;= color: rgb(54,55,55);line-height: 26px;font-size: 16px;"><strong>It pairs w= ith — not replaces — other mitochondrial tools.</strong><span> = Urolithin A drives mitophagy (clearing damaged mitochondria). MOTS-c drives= metabolic signaling and AMPK activation. SS-31 stabilizes the structural m= embrane of existing mitochondria. </span><em>These are three different mech= anisms operating on three different layers of the same system. They’r= e complementary, not competitive.</em></p><h2 class=3D"header-anchor-post" = style=3D"position: relative;font-family: 'SF Pro Display',-apple-system-hea= dline,system-ui,-apple-system,BlinkMacSystemFont,'Segoe UI',Roboto,Helvetic= a,Arial,sans-serif,'Apple Color Emoji','Segoe UI Emoji','Segoe UI Symbol';f= ont-weight: bold;-webkit-font-smoothing: antialiased;-moz-osx-font-smoothin= g: antialiased;-webkit-appearance: optimizelegibility;-moz-appearance: opti= mizelegibility;appearance: optimizelegibility;margin: 1em 0 0.625em 0;color= : rgb(54,55,55);line-height: 1.16em;font-size: calc(1.625em * 1);">What the= Research Dosing Looks Like</h2><p style=3D"margin: 0 0 20px 0;color: rgb(5= 4,55,55);line-height: 26px;font-size: 16px;"><span>Across the major clinica= l trials, the standard research dose has been </span><strong>40 mg subcutan= eously once daily</strong><span>. That’s the dose used in the Barth s= yndrome trials, the dry AMD ReCLAIM and ReCLAIM-2 trials, and the heart fai= lure trials.</span></p><p style=3D"margin: 0 0 20px 0;color: rgb(54,55,55);= line-height: 26px;font-size: 16px;">Treatment duration in the literature ra= nges from 4 weeks (cardiac trials) to 48 weeks or longer (Barth syndrome, A= MD). Effects on mitochondrial function in tissues like skeletal muscle have= been observed within hours, but structural and functional benefits in cond= itions like AMD, Barth, and kidney disease typically take months of continu= ous dosing.</p><p style=3D"margin: 0 0 20px 0;color: rgb(54,55,55);line-hei= ght: 26px;font-size: 16px;">Half-life is short — about 2 to 4 hours i= n plasma — but tissue accumulation is what matters because of the car= diolipin binding affinity. Oral bioavailability is poor; subcutaneous is th= e standard research route.</p><h2 class=3D"header-anchor-post" style=3D"pos= ition: relative;font-family: 'SF Pro Display',-apple-system-headline,system= -ui,-apple-system,BlinkMacSystemFont,'Segoe UI',Roboto,Helvetica,Arial,sans= -serif,'Apple Color Emoji','Segoe UI Emoji','Segoe UI Symbol';font-weight: = bold;-webkit-font-smoothing: antialiased;-moz-osx-font-smoothing: antialias= ed;-webkit-appearance: optimizelegibility;-moz-appearance: optimizelegibili= ty;appearance: optimizelegibility;margin: 1em 0 0.625em 0;color: rgb(54,55,= 55);line-height: 1.16em;font-size: calc(1.625em * 1);">Final Thoughts</h2><= p style=3D"margin: 0 0 20px 0;color: rgb(54,55,55);line-height: 26px;font-s= ize: 16px;"><span>SS-31 is one of the few peptides where the breadth of the= research actually matches the hype around it. The mitochondrial repair sto= ry is real, but the more interesting story is the </span><em>specific organ= systems</em><span> where it’s been studied at depth — kidneys,= eyes, hearts with genetic mitochondrial disease.</span></p><p style=3D"mar= gin: 0 0 20px 0;color: rgb(54,55,55);line-height: 26px;font-size: 16px;">If= aging is a story about energy failure cascading through one tissue at a ti= me, SS-31 is a tool that addresses the structural integrity of the energy p= roduction system itself. Not the inputs (NAD+, CoQ10), not the cleanup (mit= ophagy via UA), but the actual physical membrane where ATP gets made.</p><p= style=3D"margin: 0 0 20px 0;color: rgb(54,55,55);line-height: 26px;font-si= ze: 16px;">That’s a different layer of the cellular machinery than mo= st other longevity tools. And that’s why it deserves to be understood= for more than just “it helps mitochondria.”</p><p style=3D"mar= gin: 0 0 20px 0;color: rgb(54,55,55);line-height: 26px;font-size: 16px;"><e= m>This is for research and educational purposes only. Nothing in this piece= is medical advice, and this isn’t a recommendation to use SS-31 pers= onally. If you’re interested in the topic for any non-research reason= , that’s a conversation for a qualified medical professional who know= s your situation.</em></p><p style=3D"margin: 0 0 20px 0;color: rgb(54,55,5= 5);line-height: 26px;font-size: 16px;">If this was useful, share it with so= meone who’s been chasing the longevity rabbit hole and only knows SS-= 31 as “the mitochondria one” — and let me know in the com= ments what underrated compound you’d like me to break down next.</p><= p style=3D"margin: 0 0 20px 0;color: rgb(54,55,55);line-height: 26px;font-s= ize: 16px;">— Derek</p><div style=3D"font-size: 16px;line-height: 26p= x;"><hr style=3D"margin: 32px 0;padding: 0;height: 1px;background: rgb(0,0,= 0,.1);border: none;"></div><h2 class=3D"header-anchor-post" style=3D"positi= on: relative;font-family: 'SF Pro Display',-apple-system-headline,system-ui= ,-apple-system,BlinkMacSystemFont,'Segoe UI',Roboto,Helvetica,Arial,sans-se= rif,'Apple Color Emoji','Segoe UI Emoji','Segoe UI Symbol';font-weight: bol= d;-webkit-font-smoothing: antialiased;-moz-osx-font-smoothing: antialiased;= -webkit-appearance: optimizelegibility;-moz-appearance: optimizelegibility;= appearance: optimizelegibility;margin: 1em 0 0.625em 0;color: rgb(54,55,55)= ;line-height: 1.16em;font-size: calc(1.625em * 1);">References</h2><p style= =3D"margin: 0 0 20px 0;color: rgb(54,55,55);line-height: 26px;font-size: 16= px;"><strong>Foundational mechanism</strong></p><p style=3D"margin: 0 0 20p= x 0;color: rgb(54,55,55);line-height: 26px;font-size: 16px;"><span>Szeto HH= =2E </span><em>First-in-class cardiolip= in-protective compound as a therapeuti= c agent to restore mitochondrial bioenergetics.</em><span> Br J Pharmacol. = 2014;171(8):2029-2050.</span></p><p style=3D"margin: 0 0 20px 0;color: rgb(= 54,55,55);line-height: 26px;font-size: 16px;"><span>Zhao W, Xu Z, Cao J, et= al. </span><em>Mitochondrial protein interaction landscape of SS-31.</em><= span> Proc Natl Acad Sci USA. 2020;117(36):22247-22255.</span></p><p style= =3D"margin: 0 0 20px 0;color: rgb(54,55,55);line-height: 26px;font-size: 16= px;"><strong>Kidney disease comprehensive review</strong></p><p style=3D"ma= rgin: 0 0 20px 0;color: rgb(54,55,55);line-height: 26px;font-size: 16px;"><= span>Wang Z, Chen Z, Li B, et al. </span><em>SS-31, a Mitochondria-Targetin= g Peptide, Ameliorates Kidney Disease.</em><span> Oxidative Medicine and Ce= llular Longevity. 2022. </span><a href=3D"https://substack.com/redirect/1fe= 740c9-560b-44d2-a2bb-0adb620fe3e4?j=3DeyJ1IjoiNGl3b2U2In0.sVDxRtmZ85v8kfdam= Y0krRXGMy3p768BWtuZifRB-Zs" style=3D"color: #ff6719;text-decoration: none;"= >Full text</a></p><p style=3D"margin: 0 0 20px 0;color: rgb(54,55,55);line-= height: 26px;font-size: 16px;"><strong>Atherosclerotic renal artery stenosi= s trial</strong></p><p style=3D"margin: 0 0 20px 0;color: rgb(54,55,55);lin= e-height: 26px;font-size: 16px;"><span>Saad A, et al. </span><em>Phase 2a C= linical Trial of Mitochondrial Protection (Elamipretide) During Stent Revas= cularization in Patients With Atherosclerotic Renal Artery Stenosis.</em><s= pan> Circ Cardiovasc Interv. 2017;10(9):e005487.</span></p><p style=3D"marg= in: 0 0 20px 0;color: rgb(54,55,55);line-height: 26px;font-size: 16px;"><st= rong>Dry AMD Phase 1 trial (ReCLAIM)</strong></p><p style=3D"margin: 0 0 20= px 0;color: rgb(54,55,55);line-height: 26px;font-size: 16px;"><span>Mettu P= S, Allingham MJ, Cousins SW. </span><em>Phase 1 Clinical Trial of Elamipret= ide in Dry Age-Related Macular Degeneration and Noncentral Geographic Atrop= hy: ReCLAIM NCGA Study.</em><span> Ophthalmol Sci. 2022;2(1):100086. </span= ><a href=3D"https://substack.com/redirect/35da6e17-5c61-4644-8fcd-253165dbd= f5f?j=3DeyJ1IjoiNGl3b2U2In0.sVDxRtmZ85v8kfdamY0krRXGMy3p768BWtuZifRB-Zs" st= yle=3D"color: #ff6719;text-decoration: none;">Full text</a></p><p style=3D"= margin: 0 0 20px 0;color: rgb(54,55,55);line-height: 26px;font-size: 16px;"= ><strong>Dry AMD Phase 2 trial (ReCLAIM-2)</strong></p><p style=3D"margin: = 0 0 20px 0;color: rgb(54,55,55);line-height: 26px;font-size: 16px;"><em>ReC= LAIM-2: A Randomized Phase II Clinical Trial Evaluating Elamipretide in Age= -related Macular Degeneration, Geographic Atrophy Growth, Visual Function, = and Ellipsoid Zone Preservation.</em><span> Ophthalmology Science. 2024. </= span><a href=3D"https://substack.com/redirect/e00344cb-3f97-4bad-b525-a0e6a= e973f1f?j=3DeyJ1IjoiNGl3b2U2In0.sVDxRtmZ85v8kfdamY0krRXGMy3p768BWtuZifRB-Zs= " style=3D"color: #ff6719;text-decoration: none;">Full text</a></p><p style= =3D"margin: 0 0 20px 0;color: rgb(54,55,55);line-height: 26px;font-size: 16= px;"><strong>Barth syndrome trial (TAZPOWER)</strong></p><p style=3D"margin= : 0 0 20px 0;color: rgb(54,55,55);line-height: 26px;font-size: 16px;"><span= >Reid Thompson W, et al. </span><em>A phase 2/3 randomized clinical trial f= ollowed by an open-label extension to evaluate the effectiveness of elamipr= etide in Barth syndrome.</em><span> Genet Med. 2021;23(3):471-478.</span></= p><p style=3D"margin: 0 0 20px 0;color: rgb(54,55,55);line-height: 26px;fon= t-size: 16px;"><strong>Comprehensive 2025 review</strong></p><p style=3D"ma= rgin: 0 0 20px 0;color: rgb(54,55,55);line-height: 26px;font-size: 16px;"><= em>Elamipretide: A Review of Its Structure, Mechanism of Action, and Therap= eutic Potential.</em><span> Int J Mol Sci. 2025;26(3):944. </span><a href= =3D"https://substack.com/redirect/af9fa280-8b39-4b6c-b481-0b5be1767f23?j=3D= eyJ1IjoiNGl3b2U2In0.sVDxRtmZ85v8kfdamY0krRXGMy3p768BWtuZifRB-Zs" style=3D"c= olor: #ff6719;text-decoration: none;">Full text</a></p><p style=3D"margin: = 0 0 20px 0;color: rgb(54,55,55);line-height: 26px;font-size: 16px;"><strong= >Neuroprotection review</strong></p><p style=3D"margin: 0 0 20px 0;color: r= gb(54,55,55);line-height: 26px;font-size: 16px;"><em>Neuroprotective Effect= s of a Small Mitochondrially-Targeted Tetrapeptide Elamipretide in Neurodeg= eneration.</em><span> Front Integr Neurosci. 2021;15:747901. </span><a href= =3D"https://substack.com/redirect/b5dbd811-3f64-4b52-9c6c-c088c0c3f253?j=3D= eyJ1IjoiNGl3b2U2In0.sVDxRtmZ85v8kfdamY0krRXGMy3p768BWtuZifRB-Zs" style=3D"c= olor: #ff6719;text-decoration: none;">Full text</a></p><p style=3D"margin: = 0 0 20px 0;color: rgb(54,55,55);line-height: 26px;font-size: 16px;"><strong= >Aging skeletal muscle</strong></p><p style=3D"margin: 0 0 20px 0;color: rg= b(54,55,55);line-height: 26px;font-size: 16px;"><span>Campbell MD, Marcinek= DJ, et al. </span><em>Improving mitochondrial function with SS-31 reverses= age-related redox stress and improves exercise tolerance in aged mice.</em= ><span> Free Radic Biol Med. 2019.</span></p><p style=3D"margin: 0 0 20px 0= ;color: rgb(54,55,55);line-height: 26px;font-size: 16px;"><strong>Alzheimer= ’s disease (preclinical)</strong></p><p style=3D"margin: 0 0 20px 0;c= olor: rgb(54,55,55);line-height: 26px;font-size: 16px;"><span>Reddy PH, Man= czak M, Kandimalla R. </span><em>Mitochondria-targeted small molecule SS31:= a potential candidate for the treatment of Alzheimer’s disease.</em>= <span> Hum Mol Genet. 2017;26(8):1483-1496.</span></p><p style=3D"margin: 0= 0 20px 0;color: rgb(54,55,55);line-height: 26px;font-size: 16px;"><strong>= Independent assessment</strong></p><p style=3D"margin: 0 0 20px 0;color: rg= b(54,55,55);line-height: 26px;font-size: 16px;"><a href=3D"https://substack= =2Ecom/redirect/6a12e434-a54a-4ab4-945= b-963a3be38b6d?j=3DeyJ1IjoiNGl3b2U2In0.= sVDxRtmZ85v8kfdamY0krRXGMy3p768BWtuZifRB-Zs" style=3D"color: #ff6719;text-d= ecoration: none;">Alzheimer’s Drug Discovery Foundation Cognitive Vit= ality Report — SS-31</a></p><div class=3D"subscribe-widget is-signed-= up" data-component-name=3D"SubscribeWidget" style=3D"margin: 0 0 1em;direct= ion: ltr;font-size: 16px;line-height: 26px;margin-bottom: 0;"><div class=3D= "pencraft pc-reset button-wrapper" style=3D"text-decoration: unset;list-sty= le: none;font-size: 16px;line-height: 26px;text-align: center;cursor: point= er;border-radius: 4px;"><a class=3D"button subscribe-btn primary" href=3D"h= ttps://substack.com/redirect/2/eyJlIjoiaHR0cHM6Ly9kZXJla3BydXNraS5zdWJzdGFj= ay5jb20vc3Vic2NyaWJlP3V0bV9zb3VyY2U9cG9zdCZ1dG1fY2FtcGFpZ249ZW1haWwtY2hlY2t= vdXQmbmV4dD1odHRwcyUzQSUyRiUyRmRlcmVrcHJ1c2tpLnN1YnN0YWNrLmNvbSUyRnAlMkZzcy= 0zMS10aGUtbWl0b2Nob25kcmlhbC1wZXB0aWRlLXdpdGgmcj00aXdvZTYmdG9rZW49ZXlKMWMyV= nlYMmxrSWpveU56TTJNakl6T1Rnc0ltbGhkQ0k2TVRjM09EQTVNems1Tnl3aVpYaHdJam94Tnpn= d05qZzFPVGszTENKcGMzTWlPaUp3ZFdJdE16TTJOVE0yTnlJc0luTjFZaUk2SW1Ob1pXTnJiM1Y= wSW4wLmdYMEZMUTQwUnNwS2thSnZYMy1qWG82WmFWYTBIcU9ONmJUaW5fMENsUEkiLCJwIjoxOT= Y2OTY1MTUsInMiOjMzNjUzNjcsImYiOnRydWUsInUiOjI3MzYyMjM5OCwiaWF0IjoxNzc4MDkzO= Tk3LCJleHAiOjIwOTM2Njk5OTcsImlzcyI6InB1Yi0wIiwic3ViIjoibGluay1yZWRpcmVjdCJ9= =2EvAoG2YIG3O1lctAzIBkyi0gzj8iuBwyzBdq= vfas3hGg?&utm_medium=3Demail&utm_source= =3Dsubscribe-widget&utm_content=3D196696515" style=3D"font-family: system-u= i,-apple-system,BlinkMacSystemFont,'Segoe UI',Roboto,Helvetica,Arial,sans-s= erif,'Apple Color Emoji','Segoe UI Emoji','Segoe UI Symbol';display: inline= -block;box-sizing: border-box;cursor: pointer;border: none;border-radius: 8= px;font-size: 14px;line-height: 20px;font-weight: 600;text-align: center;op= acity: 1;outline: none;white-space: nowrap;text-decoration: none !important= ;margin: 0 auto;background-color: #FF6719;color: #ffffff !important;padding= : 12px 20px;height: auto;"><span style=3D"color: #ffffff;text-decoration: n= one;">Upgrade to paid</span></a></div></div></div></div><div class=3D"conta= iner-border" style=3D"margin: 32px 0 0;width: 100%;box-sizing: border-box;b= order-top: 1px solid #e6e6e6;font-size: 16px;line-height: 26px;"></div><div= class=3D"post-cta typography markup" style=3D"--image-offset-margin: -120p= x;text-align: initial;word-break: break-word;margin-bottom: 32px;margin: 32= px 0;font-size: 16px;line-height: 26px;"><p style=3D"color: rgb(54,55,55);m= argin: 0 auto 20px;text-align: center;width: 90%;line-height: 26px;font-siz= e: 16px;margin-top: 0;"><span class=3D"pencraft pc-reset reset-IxiVJZ" tran= slated=3D"" style=3D"list-style: none;color: unset;text-decoration: unset;m= argin: 0;">You're currently a free subscriber to <a href=3D"https://substac= k.com/redirect/0d11b96e-524f-481f-9456-e76868a9d5a7?j=3DeyJ1IjoiNGl3b2U2In0= =2EsVDxRtmZ85v8kfdamY0krRXGMy3p768BWtu= ZifRB-Zs" style=3D"color: #ff6719;text-= decoration: none;">Research Radar</a>. For the full experience, <a href=3D"= https://substack.com/redirect/2/eyJlIjoiaHR0cHM6Ly9kZXJla3BydXNraS5zdWJzdGF= jay5jb20vc3Vic2NyaWJlP3V0bV9zb3VyY2U9cG9zdCZ1dG1fY2FtcGFpZ249ZW1haWwtY2hlY2= tvdXQmbmV4dD1odHRwcyUzQSUyRiUyRmRlcmVrcHJ1c2tpLnN1YnN0YWNrLmNvbSUyRnAlMkZzc= y0zMS10aGUtbWl0b2Nob25kcmlhbC1wZXB0aWRlLXdpdGgmcj00aXdvZTYmdG9rZW49ZXlKMWMy= VnlYMmxrSWpveU56TTJNakl6T1Rnc0ltbGhkQ0k2TVRjM09EQTVNems1Tnl3aVpYaHdJam94Tnp= nd05qZzFPVGszTENKcGMzTWlPaUp3ZFdJdE16TTJOVE0yTnlJc0luTjFZaUk2SW1Ob1pXTnJiM1= YwSW4wLmdYMEZMUTQwUnNwS2thSnZYMy1qWG82WmFWYTBIcU9ONmJUaW5fMENsUEkiLCJwIjoxO= TY2OTY1MTUsInMiOjMzNjUzNjcsImYiOnRydWUsInUiOjI3MzYyMjM5OCwiaWF0IjoxNzc4MDkz= OTk3LCJleHAiOjIwOTM2Njk5OTcsImlzcyI6InB1Yi0wIiwic3ViIjoibGluay1yZWRpcmVjdCJ= 9.vAoG2YIG3O1lctAzIBkyi0gzj8iuBwyzBdqvfas3hGg?&utm_source=3Dsubstack&utm_me= dium=3Demail&utm_content=3Dpostcta" style=3D"color: #ff6719;text-decoration= : none;">upgrade your subscription.</a></span></p><p class=3D"cta-box" styl= e=3D"color: rgb(54,55,55);margin: 0 auto 20px;width: 90%;line-height: 26px;= font-size: 16px;margin-bottom: 0;text-align: center;margin-left: auto;margi= n-right: auto;"><a class=3D"button primary" role=3D"button" href=3D"https:/= /substack.com/redirect/2/eyJlIjoiaHR0cHM6Ly9kZXJla3BydXNraS5zdWJzdGFjay5jb2= 0vc3Vic2NyaWJlP3V0bV9zb3VyY2U9cG9zdCZ1dG1fY2FtcGFpZ249ZW1haWwtY2hlY2tvdXQmb= mV4dD1odHRwcyUzQSUyRiUyRmRlcmVrcHJ1c2tpLnN1YnN0YWNrLmNvbSUyRnAlMkZzcy0zMS10= aGUtbWl0b2Nob25kcmlhbC1wZXB0aWRlLXdpdGgmcj00aXdvZTYmdG9rZW49ZXlKMWMyVnlYMmx= rSWpveU56TTJNakl6T1Rnc0ltbGhkQ0k2TVRjM09EQTVNems1Tnl3aVpYaHdJam94Tnpnd05qZz= FPVGszTENKcGMzTWlPaUp3ZFdJdE16TTJOVE0yTnlJc0luTjFZaUk2SW1Ob1pXTnJiM1YwSW4wL= mdYMEZMUTQwUnNwS2thSnZYMy1qWG82WmFWYTBIcU9ONmJUaW5fMENsUEkiLCJwIjoxOTY2OTY1= MTUsInMiOjMzNjUzNjcsImYiOnRydWUsInUiOjI3MzYyMjM5OCwiaWF0IjoxNzc4MDkzOTk3LCJ= leHAiOjIwOTM2Njk5OTcsImlzcyI6InB1Yi0wIiwic3ViIjoibGluay1yZWRpcmVjdCJ9.vAoG2= YIG3O1lctAzIBkyi0gzj8iuBwyzBdqvfas3hGg?&utm_source=3Dsubstack&utm_medium=3D= email&utm_content=3Dpostcta" style=3D"font-family: system-ui,-apple-system,= BlinkMacSystemFont,'Segoe UI',Roboto,Helvetica,Arial,sans-serif,'Apple Colo= r Emoji','Segoe UI Emoji','Segoe UI Symbol';display: inline-block;box-sizin= g: border-box;cursor: pointer;border: none;height: 40px;border-radius: 8px;= font-size: 14px;line-height: 20px;font-weight: 600;text-align: center;paddi= ng: 10px 20px;margin: 0;opacity: 1;outline: none;white-space: nowrap;color:= #ffffff !important;text-decoration: none !important;background-color: #FF6= 719;">Upgrade to paid</a></p></div><table class=3D"email-ufi-2-bottom" role= =3D"presentation" width=3D"100%" border=3D"0" cellspacing=3D"0" cellpadding= =3D"0" style=3D"border-top: 1px solid rgb(0,0,0,.1);border-bottom: 1px soli= d rgb(0,0,0,.1);min-width: 100%;"><tbody><tr height=3D"16"><td height=3D"16= " style=3D"font-size:0px;line-height:0;"> </td></tr><tr><td><table cla= ss=3D"email-ufi-2-row" role=3D"presentation" width=3D"100%" border=3D"0" ce= llspacing=3D"0" cellpadding=3D"0" style=3D"border-bottom: 1px solid rgb(0,0= ,0,.1);"><tbody><tr><td width=3D"95%"><table class=3D"email-button-outline-= wrapper-full-width" role=3D"presentation" width=3D"auto" border=3D"0" cells= pacing=3D"0" cellpadding=3D"0" style=3D"width: 95%;margin: 0 auto;"><tbody>= <tr><td align=3D"center"><a class=3D"email-button-outline full-width" href= =3D"https://substack.com/app-link/post?publication_id=3D3365367&post_id=3D1= 96696515&utm_source=3Dsubstack&utm_medium=3Demail&utm_content=3Dshare&utm_c= ampaign=3Demail-share&action=3Dshare&triggerShare=3Dtrue&isFreemail=3Dtrue&= r=3D4iwoe6&token=3DeyJ1c2VyX2lkIjoyNzM2MjIzOTgsInBvc3RfaWQiOjE5NjY5NjUxNSwi= aWF0IjoxNzc4MDkzOTk3LCJleHAiOjE3ODA2ODU5OTcsImlzcyI6InB1Yi0zMzY1MzY3Iiwic3V= iIjoicG9zdC1yZWFjdGlvbiJ9.HRxTiWKoPv9sBLWcItbb-1Itf6pyvKSmY4q_P5Xrwl0" styl= e=3D"font-family: system-ui,-apple-system,BlinkMacSystemFont,'Segoe UI',Rob= oto,Helvetica,Arial,sans-serif,'Apple Color Emoji','Segoe UI Emoji','Segoe = UI Symbol';display: inline-block;font-weight: 500;border: 1px solid rgb(0,0= ,0,.1);border-radius: 9999px;text-transform: uppercase;font-size: 12px;line= -height: 12px;padding: 9px 14px;text-decoration: none;color: rgb(119,119,11= 9);width: 100%;padding-left: 0;padding-right: 0;"><img class=3D"icon" src= =3D"https://substackcdn.com/image/fetch/$s_!rmYa!,w_36,c_scale,f_png,q_auto= :good,fl_progressive:steep/https%3A%2F%2Fsubstack.com%2Ficon%2FLucideShare%= 3Fv%3D4%26height%3D36%26fill%3Dnone%26stroke%3D%2523808080%26strokeWidth%3D= 2" width=3D"18" height=3D"18" style=3D"margin-right: 8px;min-width: 18px;mi= n-height: 18px;border: none;vertical-align: middle;max-width: 18px" alt=3D"= "><span class=3D"email-button-text" style=3D"vertical-align: middle;">Share= </span></a></td></tr></tbody></table></td></tr><tr height=3D"16"><td height= =3D"16" style=3D"font-size:0px;line-height:0;"> </td></tr></tbody></ta= ble></td></tr><tr height=3D"16"><td height=3D"16" style=3D"font-size:0px;li= ne-height:0;"> </td></tr><tr><td><table role=3D"presentation" width=3D= "100%" border=3D"0" cellspacing=3D"0" cellpadding=3D"0"><tbody><tr><td><tab= le role=3D"presentation" width=3D"auto" border=3D"0" cellspacing=3D"0" cell= padding=3D"0" style=3D"margin:0 auto;"><tbody><tr><td style=3D"vertical-ali= gn:middle;"><table role=3D"presentation" width=3D"auto" border=3D"0" cellsp= acing=3D"0" cellpadding=3D"0"><tbody><tr><td align=3D"center"><a class=3D"e= mail-button-outline" href=3D"https://substack.com/app-link/post?publication= _id=3D3365367&post_id=3D196696515&utm_source=3Dsubstack&isFreemail=3Dtrue&s= ubmitLike=3Dtrue&token=3DeyJ1c2VyX2lkIjoyNzM2MjIzOTgsInBvc3RfaWQiOjE5NjY5Nj= UxNSwicmVhY3Rpb24iOiLinaQiLCJpYXQiOjE3NzgwOTM5OTcsImV4cCI6MTc4MDY4NTk5Nywia= XNzIjoicHViLTMzNjUzNjciLCJzdWIiOiJyZWFjdGlvbiJ9.KUGwtV3SeozC9VW5EhuknKTHiok= l8q24oZ4PXtizIAU&utm_medium=3Demail&utm_campaign=3Demail-reaction&r=3D4iwoe= 6" style=3D"font-family: system-ui,-apple-system,BlinkMacSystemFont,'Segoe = UI',Roboto,Helvetica,Arial,sans-serif,'Apple Color Emoji','Segoe UI Emoji',= 'Segoe UI Symbol';display: inline-block;font-weight: 500;border: 1px solid = rgb(0,0,0,.1);border-radius: 9999px;text-transform: uppercase;font-size: 12= px;line-height: 12px;padding: 9px 14px;text-decoration: none;color: rgb(119= ,119,119);"><img class=3D"icon" src=3D"https://substackcdn.com/image/fetch/= $s_!PeVs!,w_36,c_scale,f_png,q_auto:good,fl_progressive:steep/https%3A%2F%2= Fsubstack.com%2Ficon%2FLucideHeart%3Fv%3D4%26height%3D36%26fill%3Dnone%26st= roke%3D%2523808080%26strokeWidth%3D2" width=3D"18" height=3D"18" style=3D"m= argin-right: 8px;min-width: 18px;min-height: 18px;border: none;vertical-ali= gn: middle;max-width: 18px" alt=3D""><span class=3D"email-button-text" styl= e=3D"vertical-align: middle;">Like</span></a></td></tr></tbody></table></td= ><td width=3D"8" style=3D"min-width:8px;"></td><td style=3D"vertical-align:= middle;"><table role=3D"presentation" width=3D"auto" border=3D"0" cellspaci= ng=3D"0" cellpadding=3D"0"><tbody><tr><td align=3D"center"><a class=3D"emai= l-button-outline" href=3D"https://substack.com/app-link/post?publication_id= =3D3365367&post_id=3D196696515&utm_source=3Dsubstack&utm_medium=3Demail&isF= reemail=3Dtrue&comments=3Dtrue&token=3DeyJ1c2VyX2lkIjoyNzM2MjIzOTgsInBvc3Rf= aWQiOjE5NjY5NjUxNSwiaWF0IjoxNzc4MDkzOTk3LCJleHAiOjE3ODA2ODU5OTcsImlzcyI6InB= 1Yi0zMzY1MzY3Iiwic3ViIjoicG9zdC1yZWFjdGlvbiJ9.HRxTiWKoPv9sBLWcItbb-1Itf6pyv= KSmY4q_P5Xrwl0&r=3D4iwoe6&utm_campaign=3Demail-half-magic-comments&action= =3Dpost-comment&utm_source=3Dsubstack&utm_medium=3Demail" style=3D"font-fam= ily: system-ui,-apple-system,BlinkMacSystemFont,'Segoe UI',Roboto,Helvetica= ,Arial,sans-serif,'Apple Color Emoji','Segoe UI Emoji','Segoe UI Symbol';di= splay: inline-block;font-weight: 500;border: 1px solid rgb(0,0,0,.1);border= -radius: 9999px;text-transform: uppercase;font-size: 12px;line-height: 12px= ;padding: 9px 14px;text-decoration: none;color: rgb(119,119,119);"><img cla= ss=3D"icon" src=3D"https://substackcdn.com/image/fetch/$s_!x1tS!,w_36,c_sca= le,f_png,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack.com%2Ficon= %2FLucideComments%3Fv%3D4%26height%3D36%26fill%3Dnone%26stroke%3D%252380808= 0%26strokeWidth%3D2" width=3D"18" height=3D"18" style=3D"margin-right: 8px;= min-width: 18px;min-height: 18px;border: none;vertical-align: middle;max-wi= dth: 18px" alt=3D""><span class=3D"email-button-text" style=3D"vertical-ali= gn: middle;">Comment</span></a></td></tr></tbody></table></td><td width=3D"= 8" style=3D"min-width:8px;"></td><td style=3D"vertical-align:middle;"><tabl= e role=3D"presentation" width=3D"auto" border=3D"0" cellspacing=3D"0" cellp= adding=3D"0"><tbody><tr><td align=3D"center"><a class=3D"email-button-outli= ne" href=3D"https://substack.com/redirect/2/eyJlIjoiaHR0cHM6Ly9vcGVuLnN1YnN= 0YWNrLmNvbS9wdWIvZGVyZWtwcnVza2kvcC9zcy0zMS10aGUtbWl0b2Nob25kcmlhbC1wZXB0aW= RlLXdpdGg_dXRtX3NvdXJjZT1zdWJzdGFjayZ1dG1fbWVkaXVtPWVtYWlsJnV0bV9jYW1wYWlnb= j1lbWFpbC1yZXN0YWNrLWNvbW1lbnQmYWN0aW9uPXJlc3RhY2stY29tbWVudCZyPTRpd29lNiZ0= b2tlbj1leUoxYzJWeVgybGtJam95TnpNMk1qSXpPVGdzSW5CdmMzUmZhV1FpT2pFNU5qWTVOalV= 4TlN3aWFXRjBJam94TnpjNE1Ea3pPVGszTENKbGVIQWlPakUzT0RBMk9EVTVPVGNzSW1semN5ST= ZJbkIxWWkwek16WTFNelkzSWl3aWMzVmlJam9pY0c5emRDMXlaV0ZqZEdsdmJpSjkuSFJ4VGlXS= 29QdjlzQkxXY0l0YmItMUl0ZjZweXZLU21ZNHFfUDVYcndsMCIsInAiOjE5NjY5NjUxNSwicyI6= MzM2NTM2NywiZiI6dHJ1ZSwidSI6MjczNjIyMzk4LCJpYXQiOjE3NzgwOTM5OTcsImV4cCI6MjA= 5MzY2OTk5NywiaXNzIjoicHViLTAiLCJzdWIiOiJsaW5rLXJlZGlyZWN0In0.pszfW7UJJ1qzAx= ixJDiJhNTnkoY1IinyibpJgfGGp2s?&utm_source=3Dsubstack&utm_medium=3Demail" st= yle=3D"font-family: system-ui,-apple-system,BlinkMacSystemFont,'Segoe UI',R= oboto,Helvetica,Arial,sans-serif,'Apple Color Emoji','Segoe UI Emoji','Sego= e UI Symbol';display: inline-block;font-weight: 500;border: 1px solid rgb(0= ,0,0,.1);border-radius: 9999px;text-transform: uppercase;font-size: 12px;li= ne-height: 12px;padding: 9px 14px;text-decoration: none;color: rgb(119,119,= 119);"><img class=3D"icon" src=3D"https://substackcdn.com/image/fetch/$s_!u= bXF!,w_36,c_scale,f_png,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubs= tack.com%2Ficon%2Fnotes__NoteRestackIcon%3Fv%3D4%26height%3D36%26fill%3Dnon= e%26stroke%3D%2523808080%26strokeWidth%3D2%26strokeLinecap%3Dround%26stroke= Linejoin%3Dround" width=3D"18" height=3D"18" alt=3D"" style=3D"margin-right= : 8px;min-width: 18px;min-height: 18px;max-width: 550px;border: none !impor= tant;vertical-align: middle;"><span class=3D"email-button-text" style=3D"ve= rtical-align: middle;">Restack</span></a></td></tr></tbody></table></td></t= r></tbody></table></td><td align=3D"right"><table role=3D"presentation" wid= th=3D"auto" border=3D"0" cellspacing=3D"0" cellpadding=3D"0"><tbody><tr></t= r></tbody></table></td></tr></tbody></table></td></tr><tr height=3D"16"><td= height=3D"16" style=3D"font-size:0px;line-height:0;"> </td></tr></tbo= dy></table><div class=3D"footer footer-ZM59BM" style=3D"color: rgb(119,119,= 119);text-align: center;font-size: 16px;line-height: 26px;padding: 24px0;">= <div style=3D"font-size: 16px;line-height: 26px;padding-bottom: 24px"><p cl= ass=3D"pencraft pc-reset color-secondary-ls1g8s size-12-mmZ61m reset-IxiVJZ= small meta-B2bqa5" style=3D"list-style: none;font-family: system-ui,-apple= -system,BlinkMacSystemFont,'Segoe UI',Roboto,Helvetica,Arial,sans-serif,'Ap= ple Color Emoji','Segoe UI Emoji','Segoe UI Symbol';padding-bottom: 0;font-= size: 12px;line-height: 16px;margin: 0;color: rgb(119,119,119);text-decorat= ion: unset;">© 2026 <span>Derek Pruski</span><br>548 Market Street PMB= 72296, San Francisco, CA 94104 <br><a href=3D"https://substack.com/redirec= t/2/eyJlIjoiaHR0cHM6Ly9kZXJla3BydXNraS5zdWJzdGFjay5jb20vYWN0aW9uL2Rpc2FibGV= fZW1haWw_dG9rZW49ZXlKMWMyVnlYMmxrSWpveU56TTJNakl6T1Rnc0luQnZjM1JmYVdRaU9qRT= VOalk1TmpVeE5Td2lhV0YwSWpveE56YzRNRGt6T1RrM0xDSmxlSEFpT2pFNE1EazJNams1T1Rjc= 0ltbHpjeUk2SW5CMVlpMHpNelkxTXpZM0lpd2ljM1ZpSWpvaVpHbHpZV0pzWlY5bGJXRnBiQ0o5= LmVqdVlaRmNfOG5uTHVNRTNPWG9PR1Rtbm43cEtQcGFTOFFCcVY4bzh5QUkiLCJwIjoxOTY2OTY= 1MTUsInMiOjMzNjUzNjcsImYiOnRydWUsInUiOjI3MzYyMjM5OCwiaWF0IjoxNzc4MDkzOTk3LC= JleHAiOjIwOTM2Njk5OTcsImlzcyI6InB1Yi0wIiwic3ViIjoibGluay1yZWRpcmVjdCJ9.kgZ8= g1GRtt1A082v6ZOlhya_r3rGs3aCerucd5uuJIE?" style=3D"color: #ff6719;text-deco= ration: none;"><span style=3D"color: rgb(119,119,119);text-decoration: unde= rline;">Unsubscribe</span></a></p></div><p class=3D"footerSection-EHR0jG sm= all powered-by-substack" style=3D"padding: 0 24px;font-size: 12px;line-heig= ht: 20px;margin: 0;color: rgb(119,119,119);font-family: system-ui,-apple-sy= stem,BlinkMacSystemFont,'Segoe UI',Roboto,Helvetica,Arial,sans-serif,'Apple= Color Emoji','Segoe UI Emoji','Segoe UI Symbol';padding-bottom: 0;margin-t= op: 0;"><a href=3D"https://substack.com/redirect/2/eyJlIjoiaHR0cHM6Ly9zdWJz= dGFjay5jb20vc2lnbnVwP3V0bV9zb3VyY2U9c3Vic3RhY2smdXRtX21lZGl1bT1lbWFpbCZ1dG1= fY29udGVudD1mb290ZXImdXRtX2NhbXBhaWduPWF1dG9maWxsZWQtZm9vdGVyJmZyZWVTaWdudX= BFbWFpbD10anBodWhzQGdtYWlsLmNvbSZyPTRpd29lNiIsInAiOjE5NjY5NjUxNSwicyI6MzM2N= TM2NywiZiI6dHJ1ZSwidSI6MjczNjIyMzk4LCJpYXQiOjE3NzgwOTM5OTcsImV4cCI6MjA5MzY2= OTk5NywiaXNzIjoicHViLTAiLCJzdWIiOiJsaW5rLXJlZGlyZWN0In0.0gPGJCK71Z37jgb1Qh2= _On8VddYthdE-G4SiCDa99sc?" style=3D"color: #ff6719;text-decoration: none;di= splay: inline-block;margin: 0 4px;"><img src=3D"https://substackcdn.com/ima= ge/fetch/$s_!LkrL!,w_270,c_limit,f_auto,q_auto:good,fl_progressive:steep/ht= tps%3A%2F%2Fsubstack.com%2Fimg%2Femail%2Fpublish-button%402x.png" srcset=3D= "https://substackcdn.com/image/fetch/$s_!wgfj!,w_135,c_limit,f_auto,q_auto:= good,fl_progressive:steep/https%3A%2F%2Fsubstack.com%2Fimg%2Femail%2Fpublis= h-button.png, https://substackcdn.com/image/fetch/$s_!LkrL!,w_270,c_limit,f= _auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack.com%2Fimg%2Fe= mail%2Fpublish-button%402x.png 2x, https://substackcdn.com/image/fetch/$s_!= KjtY!,w_405,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fs= ubstack.com%2Fimg%2Femail%2Fpublish-button%403x.png 3x" width=3D"135" alt= =3D"Start writing" height=3D"40" style=3D"max-width: 550px;border: none !im= portant;vertical-align: middle;"></a></p></div></div></td><td></td></tr></t= body></table><img src=3D"https://eotrx.substackcdn.com/o/ec7348684c94841c/p= =2Egif?token=3DeyJtIjoiPDIwMjYwNTA2MTg1O= TIxLjMuMTY1OTFhZWQ3ODQ5OTE4NUBtZy1kMC= 5zdWJzdGFjay5jb20-IiwidSI6MjczNjIyMzk4LCJyIjoidGpwaHVoc0BnbWFpbC5jb20iLCJkI= joibWctZDAuc3Vic3RhY2suY29tIiwicCI6MTk2Njk2NTE1LCJ0IjoibmV3c2xldHRlciIsImEi= OiJldmVyeW9uZSIsInMiOjMzNjUzNjcsImMiOiJwb3N0IiwiZiI6dHJ1ZSwicG9zaXRpb24iOiJ= ib3R0b20iLCJpYXQiOjE3NzgwOTM5OTcsImV4cCI6MTc4MDY4NTk5NywiaXNzIjoicHViLTAiLC= JzdWIiOiJlbyJ9.e48CUdEahcO0toD8SG-EaTuLV9rZSfuh76I7DDVFiow" alt=3D"" width= =3D"1" height=3D"1" border=3D"0" style=3D"height:1px !important;width:1px != important;border-width:0 !important;margin-top:0 !important;margin-bottom:0= !important;margin-right:0 !important;margin-left:0 !important;padding-top:= 0 !important;padding-bottom:0 !important;padding-right:0 !important;padding= -left:0 !important;"/><img width=3D"1" height=3D"1" alt=3D"" src=3D"https:/= /email.mg-d0.substack.com/o/eJxE0NuuqyAQxvGnKXfbMBzlgmcxCKNlq2A4dMW3X7Ftsm6= _Sf75ZbxruOZy2TPXRoJV3C0yELSg9UgNN2YkeLi4TysmLK5hmFz7u2otJHlaHQwYtzC5MCGAMw= CvhQAQwWvOtSTRMsoUlVTBKA2DgQ-gpAGHQY_CGBjlQ9Bj_RfoUPtcm_Pb4PNBYp2Wgm-CbaUju= aGT6yFi8mjxheXK6TvHYMEoZZQE-VnadaJN-FN3bA0LOfs8-XwcPcV2TZjcvGP4hvu8R-9azOkO= ca4kV5oU2_6fz_6sD0HXm_Fm1T6HfLiYbMCC21l63SJpnzf2iuVOMM0VY9yM5GXZbwAAAP__NK1= 2ig"></body></html> --c3d5585fa2c80c1ed93e1e7208fe36fab5c3c38cab25194c1c1544e34d5d--